Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12777 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Nov 2026, 03:17 UTC

2556

Shown in this register

most recently authorised

12,777

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1075 France 930 Germany 898 Italy 778 Poland 619 Netherlands 547

Narrow the register

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials in this register

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase IV

A randomised, double-blind, three parallel-group, placebo controlled superiority trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in iron deficient FRAIL elderly IndiviDuals with cardiovascular disease (FRAIL-ID trial)

2025-521570-34-00Frailty with Iron Deficiency in Elderly Patients with Cardi…

Wroclaw Medical University

Nutritional and Metabolic Diseases

Poland

05/06/2026

Phase II

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer

2026-526494-42-00Gastric cancer

Varsinais-Suomen hyvinvointialue

Neoplasms

Finland

05/06/2026

Phase II

A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

2026-525817-29-00Multiple Sclerosis; Primary Progressive Multiple Sclerosis;…

Sundance Biosciences Inc.

Nervous System Diseases

Finland

05/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

2025-523912-35-00Narcolepsy Type 2

Alkermes Inc.

Nervous System Diseases

Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland

04/06/2026

Phase IV

Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE

2025-524110-28-00Incidental Subsegmental Pulmonary Embolism in cancer patien…

DrugsDalteparin·Tinzaparin·Edoxaban·Enoxaparin

Region Hovedstaden

Cardiovascular Diseases

Denmark

04/06/2026

Phase III

TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH

2023-509795-42-00Aneurysmal subarachnoid hemorrhage

DrugTicagrelor

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

04/06/2026

Phase I/II

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.

2025-524232-20-00Patients with poor prognostic ovarian cancers based on the …

DrugsUbamatamab·Filgrastim·Paclitaxel·Bevacizumab

Asso De Recherche Cancers Gynecologiques

Neoplasms

France

04/06/2026

Phase I

Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions

2026-525780-41-00Not applicable (submitted trial is a bioavailability trial …

Laboratorios Cinfa S.A.

Nervous System Diseases

Czechia

04/06/2026

Phase I

T cell imaging in kidney transplantation (TIK)

2025-522490-11-00Renal allograft rejection

Radboud universitair medisch centrum Stichting

Immune system processes

Netherlands

04/06/2026

Phase I/II

A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults

2025-524456-58-00Respiratory Syncytial Virus Infections+Metapneumovirus

GlaxoSmithKline Biologicals

Respiratory Tract Diseases

Belgium

04/06/2026

Phase II

Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries

2026-525554-11-00Traumatic brain injury

Astrocyte Pharmaceuticals Inc.

Nervous System Diseases

Netherlands

04/06/2026

Phase III

Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial

2024-518706-41-01Cardiovascular disease

Vaestra Goetalandsregionen

Diagnosis

Sweden

03/06/2026

Phase I/II

A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.

2025-523939-18-00Amyotrofic Lateral Sclerosis (ALS)

DrugRiluzole

Nura Bio Inc.

Nervous System Diseases

Poland, Netherlands, Italy, Spain

03/06/2026

Phase III

Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE)

2026-525906-37-00Parkinson's Disease

DrugMontelukast

Karolinska University Hospital

Nervous System Diseases

Sweden

03/06/2026

Phase III

A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

2025-524575-22-00Neovascular age-related macular degeneration (NVAMD)

Eyebiotech Limited

Eye Diseases

Spain, Poland, Estonia, Latvia, Germany

03/06/2026

Phase I/II

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.

2025-523590-42-00Locally Advanced or Metastatic Solid Tumors

Crescent Biopharma Inc.

Neoplasms

Spain, Ireland, Italy, France, Romania

02/06/2026

Phase III

A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)

2025-523892-50-00Multiple Sclerosis

DrugRituximab

Region Stockholm – SLSO

Nervous System Diseases

Sweden

02/06/2026

Phase II

Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers

2025-524720-22-00patients with head and neck squamous cell carcinoma (HNSCC)

DrugBotulinum toxin type A

Fakultni Nemocnice Kralovske Vinohrady

Otorhinolaryngologic Diseases

Czechia

02/06/2026

Phase I

Randomized, open-label, multiple dose, two-period, two-treatment, cross-over pharmacodynamic study in healthy male and female participants under fasting conditions.

2026-526556-31-00Pharmacodynamic study under fasting condition.

Adamed Pharma S.A.

Cardiovascular Diseases

Czechia

02/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-523911-13-00Narcolepsy Type 1

Alkermes Inc.

Nervous System Diseases

Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland

02/06/2026

Phase III

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

2025-523670-17-00Systemic lupus erythematosus

AstraZeneca AB

Immune System Diseases

Poland, Germany, Italy, France, Spain

02/06/2026

Phase I

An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.

2025-524219-35-00treatment of myasthenia gravis

Vianex S.A.

Musculoskeletal Diseases

Czechia

02/06/2026

Phase II

A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson’s disease – SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial

2025-523570-17-00Parkinson's Disease

Helse Bergen HF

Nervous System Diseases

Norway

02/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS

2025-522434-32-00Hemophilia A Without Inhibitors

F. Hoffmann-La Roche AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary

01/06/2026

Phase I

GRAIN, Prospective Pilot Study

2025-524470-41-00Esophageal dysplasia, Barrett's esophagus, Esophageal adeno…

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

01/06/2026

Phase III

Post-INFECT: Investigating Neuroinflammation and its eFEcts in post-COVID syndrome: an imaging sTudy

2025-522349-23-00post-COVID syndrome

Amsterdam UMC Stichting

Virus Diseases

Netherlands

01/06/2026

Phase III

Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests

2025-523426-40-00Allergy to Lepidoglyphus destructor

Inmunotek S.L.

Immune System Diseases

Spain

01/06/2026

Phase IV

IJAMP-Trial

2025-523131-19-00prick test-induced itch

Johannes Kepler University Linz

Skin and Connective Tissue Diseases

Austria

01/06/2026

Phase III

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

2022-502365-26-00Asthma

DrugSalbutamol

Novartis Pharma AG

Respiratory Tract Diseases

Poland, France, Slovakia, Spain, Hungary, Germany, Romania

01/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A

2025-522435-33-00Hemophilia A

F. Hoffmann-La Roche AG

Hemic and Lymphatic Diseases

Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France

01/06/2026

Phase II

Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

2025-521126-15-00Chronic Myeloid Leukemia

Grupo Espanol De Leucemia Mieloide Cronica (GELMC)

Neoplasms

Spain

01/06/2026

Phase III

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

2025-524241-27-00Treatment-naїve mantle cell lymphoma (MCL)

DrugsOrelabrutinib·Bendamustine·Rituximab

Innocare Pharma Inc.

Neoplasms

Poland, France, Czechia, Spain, Romania

01/06/2026

Phase I/II

A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease

2025-524082-25-00Late-Onset Pompe Disease

Denali Therapeutics Inc.

Musculoskeletal Diseases

Germany, Netherlands

01/06/2026

Phase II

Sublingual Birch Immunotherapy for Pollen-associated Food Allergy

2025-523653-34-00Birch pollen Allergy, Pollen-associated Food Allergy

DrugMannitol

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Immune System Diseases

Germany

29/05/2026

Phase I/II

An open-label, single-arm, phase 1/2 first-in-human study to assess the safety and efficacy of autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene (SGX-001) in paediatric and adult patients with chronic granulomatous disease caused by p47phox deficiency

2025-524423-50-00Chronic granulomatous disease (CGD) caused by p47phox defic…

Somagenetix AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Germany, Spain

29/05/2026

Phase II

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia

DrugsAsparaginase Erwinia chrysanthemi·Tofacitinib·Everolimus·Azacitidine

Centre Hospitalier De Versailles

Hemic and Lymphatic Diseases

Germany, France, Czechia, Netherlands, Spain

29/05/2026

Phase II

Leveraging the neural mechanisms of social reward for drug relapse prevention

2023-504518-31-01substance use disorder

DrugOxytocin

Fondazione Santa Lucia IRCCS

Mental Disorders

Italy

29/05/2026

Phase II

Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS

2026-525613-31-00Restless legs syndrome

DrugFerric Carboxymaltose

Centre Hospitalier Universitaire De Montpellier

Nervous System Diseases

France

29/05/2026

Phase IV

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study

2025-524395-30-00heart failure

DrugsMetformin·Dapagliflozin

Centre Hospitalier Universitaire De Toulouse

Cardiovascular Diseases

France

29/05/2026

Phase I/II

C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.

2025-523523-21-00Locally Advanced or Metastatic Urothelial Cancer

Pfizer Inc.

Neoplasms

Netherlands, Spain

29/05/2026

Phase III

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

2025-524062-16-00Schizophrenia and Autism Spectrum Disorder (ASD)

Bristol-Myers Squibb Services Unlimited Company

Nervous System Diseases

Romania

29/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

2025-523555-66-00Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharma AG

Neoplasms

Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France

29/05/2026

Phase II

J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

2025-524726-18-00Vitiligo, Non-Segmental Vitiligo (NSV)

Eli Lilly & Co.

Immune System Diseases

Poland, Belgium

29/05/2026

Phase II

Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.

2026-525317-31-00Retractile Capsulitis

Centre Hospitalier Universitaire De Nantes

Musculoskeletal Diseases

France

29/05/2026

Phase III

Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)

2026-526142-27-01Deformity, Osteoarthritis

HUS-yhtymae

Therapeutics

Finland

29/05/2026

Phase III

A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.

2025-524580-21-00Grass pollen induced allergic rhinitis or rhinoconjunctivit…

Inmunotek S.L.

Immune System Diseases

Germany

29/05/2026

Phase I

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

2025-523873-41-00Overweight Obesity

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Germany, Sweden

29/05/2026

Phase III

COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial

2025-522956-25-00Chronic pancreatitis

DrugCelecoxib

Odense University Hospital

Digestive System Diseases

Denmark

29/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis

2025-523400-72-00Cystic fibrosis

Vertex Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark

29/05/2026

Phase III

Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)

2026-525263-41-00Hodgkin lymphoma

Polska Grupa Badawcza Chloniakow

Neoplasms

Poland

29/05/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis

2025-523950-15-01Generalized Myasthenia Gravis

Vertex Pharmaceuticals Inc.

Nervous System Diseases

Poland

29/05/2026

Phase I

A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis

2025-525113-22-00Rheumatoid Arthritis

Neurocrine Biosciences Inc.

Immune System Diseases

Poland, Romania

29/05/2026

Phase I/II

Prospective, multicentre, two-arms, I/II phase study to Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC)

2024-513917-11-01Adult patients with chronic lymphocytic leukemia/small lymp…

DrugsObinutuzumab·Daratumumab·Venetoclax

Uniwersytet Medyczny W Lublinie

Hemic and Lymphatic Diseases

Poland

29/05/2026

Phase II

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

2025-524378-40-00Locally advanced high‑risk stage III rectal adenocarcinoma …

DrugKortuc

Institut Gustave Roussy

Neoplasms

France

28/05/2026

Phase II

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)

2025-523539-20-00Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences Inc.

Neoplasms

Bulgaria, France, Spain

28/05/2026

Phase III

A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.

2026-525291-26-00Helicobacter Pylori Infection

DrugMetronidazole

Verisfield Single Member S.A.

Bacterial Infections and Mycoses

Greece

28/05/2026

Phase IV

A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency

2025-522964-33-00Alpha1 antitrypsin deficiency, Emphysema, Alpha1-proteinase…

CSL Behring LLC

Respiratory Tract Diseases

Denmark

28/05/2026

Phase IV

A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial

2026-525640-14-00Candidemia

DrugsCaspofungin·Sodium Lactate

University Of Cologne

Bacterial Infections and Mycoses

Germany

28/05/2026

Phase IV

A randomized, Phase 4, double-blind, placebo-controlled, 6-arm crossover study to investigate the systemic effect of lidocaine and ropivacaine when used for Transversus Abdominis Plane (TAP) blocks on hyperalgesia and pain perception in healthy volunteers aged 18 to 64 years.

2025-520910-67-01Acute pain

DrugsRopivacaine·Lidocaine

Oslo University Hospital HF

Anesthesia and Analgesia

Norway

28/05/2026

Phase IV

Optimising the protocol of labour induction using misoprostol – randomised open-label clinical trial (OPTIMISO)

2026-525770-19-00Labour induction

Fakultni Nemocnice Brno

Female Urogenital Diseases and Pregnancy Complications

Czechia

28/05/2026

Phase I/II

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma

2025-523005-15-00Non-Hodgkin Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

Poland, Italy, France, Germany, Spain

28/05/2026

Phase II

Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)

2025-522781-77-01Epstein-Barr virus infection

Helse Bergen HF

Virus Diseases

Norway

28/05/2026

Phase I

Bioavailability, Biopotency and Food effect study of SCD0503 compared to subcutaneous regular human insulin

2024-519502-12-00Type 1 diabetes

Samchundang Pharm. Co. Ltd.

Nutritional and Metabolic Diseases

Germany

28/05/2026

Phase II

Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.

2024-516796-33-00The medical condition studied in IMMUNO-BOS is Bronchioliti…

Hospital Foch

Respiratory Tract Diseases

France

27/05/2026

Phase I/II

A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC

2025-523276-23-00Extensive stage small cell lung cancer

DrugsBendamustine·Tocilizumab·Fludarabine·Cyclophosphamide

Novartis Pharma AG

Neoplasms

Spain, France

27/05/2026

Phase II

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials

2025-523579-47-00moderate to severe rheumatoid arthritis (RA)

DrugAfimkibart

F. Hoffmann-La Roche AG

Immune System Phenomena

Italy, Spain, Germany, France, Denmark, Poland, Belgium

27/05/2026

Phase I/II

Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas

2025-523997-18-00Sarcoma

Glaxosmithkline Research & Development Limited

Neoplasms

France

27/05/2026

Phase III

A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

2025-521590-13-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary

27/05/2026

Phase II

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

2025-521757-16-00Hallucinations and Delusions Associated with Alzheimer’s Di…

Maplight Therapeutics Inc.

Mental Disorders

Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary

27/05/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

2025-522949-22-00Duchenne muscular dystrophy

Solid Biosciences Inc.

Musculoskeletal Diseases

Spain, Netherlands, France, Italy, Belgium, Germany

26/05/2026

Phase I/II

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

2025-522339-32-00Neoplasm malignant

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia

26/05/2026

Phase II

POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug

2023-506420-93-00Chronic recurrent multifocal osteomyelitis (CRMO)

DrugZoledronic Acid

Assistance Publique Hopitaux De Paris

Musculoskeletal Diseases

France

26/05/2026

Phase I

A study comparing different dosage forms of midazolam and how they are taken up in the body.

2025-524999-37-00Bioavailability Study under Fasting Conditions

MIDAS Pharma GmbH

Anesthesia and Analgesia

Czechia

26/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

2025-524040-35-00Severe uncontrolled asthma

Generate Biomedicines Inc.

Respiratory Tract Diseases

Italy, Slovakia, Spain, Ireland, Belgium, France, Estonia

26/05/2026

Phase I

First-in-human study to assess the safety and feasibility of intra-articular administration of allogeneic engineered gingival fibroblasts (aeGF) in participants with knee osteoarthritis.

2026-525604-99-00Knee osteoarthritis

Scarcell Therapeutics

Musculoskeletal Diseases

Denmark

26/05/2026

Phase IV

Platelet function testing in outpatients after heart transplantation on aspirin therapy

2025-521699-71-01Patients who have undergone heart transplantation.

Medical University Of Vienna

Cardiovascular Diseases

Austria

25/05/2026

Phase III

D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation

2025-522469-31-00Allergy to Dermatophagoides pteronyssinus, Allergy to Derma…

Inmunotek S.L.

Immune System Diseases

Spain

25/05/2026

Phase II

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

2025-524181-26-00relapsed/refractory multiple myeloma

C4 Therapeutics Inc.

Hemic and Lymphatic Diseases

Italy, France, Spain, Poland

25/05/2026

Phase III

Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices (OPIAC)

2025-524884-18-01Intracranial aneurysms

Les Hopitaux Universitaires De Strasbourg

Nervous System Diseases

France

22/05/2026

Phase II

UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis

2025-521982-29-00Adult patients with advanced hormone receptor positive (HR+…

DrugsPrifetrastat·Fulvestrant

Unicancer

Neoplasms

France

22/05/2026

Phase I

A study in healthy people to compare two tablet formulations of pramipexole

2026-525704-98-00Healthy volunteer trial

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

22/05/2026

Phase IV

Reassessment of statin-associated musscle symptoms in adults with familial hypercholesterolemia: A phase IV randomized double-blinded n-of-1 crossover trial including periods with atorvastatin, placebo and no study treatment

2025-521589-83-00Familial hypercholesterolaemia

DrugAtorvastatin

Oslo University Hospital HF

Cardiovascular Diseases

Norway

22/05/2026

Phase I

A study to test single and multiple doses of MER511 given to adults with Graves’ disease

2025-523823-23-00Graves’ disease

Merida Biosciences Inc.

Immune System Diseases

Spain

22/05/2026

Phase I

Thorough QT/QTc study with GLPG3667, placebo, and active comparator in healthy subjects

2026-525788-42-00Healthy volunteers

Galapagos

Not possible to specify

Netherlands

22/05/2026

Phase I

A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

2025-524564-38-00Neuropsychiatric indications and potentially other conditio…

Bristol-Myers Squibb Services Unlimited Company

Behavior and Behavior Mechanisms

Belgium

22/05/2026

Phase IV

Comparing intraoperative indocyanine green fluorescence imaging with standard clinical assessment for flap perfusion in head and neck reconstruction: A randomised controlled Trial (VISION Trial)

2025-524710-29-00Head and neck cancer

Region Skane

Neoplasms

Sweden

22/05/2026

Phase IV

A randomized, placebo-controlled, blinded, parallel-group clinical trial to assess the efficacy of N-acetylcysteine in adults with acute infections or sepsis and evidence of liver dysfunction: the IMPACT-NAC trial

2026-525895-25-00Acute infection, Sepsis

Region Hovedstaden

Bacterial Infections and Mycoses

Denmark

22/05/2026

Phase I

A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 mg film-coated tablets (Antibiotice SA) vs. Normix® 200 mg, film- coated tablets (Alfasigma S.P.A) in healthy subjects under fed conditions

2025-525078-12-00healthy subjects

Antibiotice S.A.

Bacterial Infections and Mycoses

Romania

22/05/2026

Phase I

Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

2026-525448-14-00Parkinson disease

Orion Corporation

Nervous System Diseases

Czechia

22/05/2026

Phase II

Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression

2025-521563-13-01Paediatric myopia

Laboratoires Thea

Eye Diseases

Ireland, Austria

22/05/2026

Phase IV

Exogenous progesterone as ovulation trigger – a pilot study

2025-523850-15-00Infertility

Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda.

Female Urogenital Diseases and Pregnancy Complications

Portugal

22/05/2026

Phase I

150 mg CIT-013 phase 1 trial

2026-526153-34-00Immune mediated inflammatory diseases

Citryll B.V.

Immune System Diseases

Netherlands

22/05/2026

Phase III

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

2025-523576-23-00Unresectable Stage III non-small cell lung cancer without p…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland

22/05/2026

Phase II

A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).

2025-523672-23-00Metastatic Castrate Sensitive Prostate Cancer - mCSPC

UroTrials GmbH, AIO-Studien gGmbH

Male Urogenital Diseases

Germany

22/05/2026

Phase I/II

A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours

2025-524620-22-00Neoplasms benign malignant and unspecified (incl. cysts and…

DrugsODM-212·Sotorasib·Ipilimumab·Nivolumab

Orion Corporation

Neoplasms

Finland, Denmark, Spain, France

22/05/2026

Phase II

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

DrugPembrolizumab

Eikon Therapeutics Inc.

Neoplasms

Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland

21/05/2026

Phase I

Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare

2026-525200-99-00Chronic allergic rhinitis

Dianosic

Respiratory Tract Diseases

Netherlands

21/05/2026

Phase II

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

2025-524367-20-00Adult patients with primary mitochondrial disease

Pharming Technologies B.V.

Metabolism

Belgium, Germany, Czechia, Spain, Denmark, Italy, France, Netherlands

21/05/2026

Phase I

First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

2025-524165-25-00Neoplasms

Glaxosmithkline Research & Development Limited

Neoplasms

Spain, Denmark, Finland, France

21/05/2026

Phase IV

Effect of an adjunctive intervention on the tolerability of semaglutide in overweight adults without diabetes: a prospective, randomised, double-blind, single-centre, placebo-controlled clinical trial (SEMTOL)

2025-524612-11-00Overweight and obesity

University Of Tartu

Nutritional and Metabolic Diseases

Estonia

21/05/2026

Phase IV

Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma

2026-525267-40-00Renal cell carcinoma

Centro Di Riferimento Oncologico Di Aviano

Neoplasms

Italy

21/05/2026

Phase II

An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up

2025-523280-38-00Thyroid Eye Disease

Amgen Inc.

Eye Diseases

Spain, Poland, France, Italy, Greece

20/05/2026

Phase III

An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib

2025-524078-40-00Chronic Spontaneous Urticaria

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, France, Poland, Bulgaria, Czechia

20/05/2026

Phase I/II

An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)

2025-524635-39-00X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)

Fondazione Telethon Ets, San Raffaele Hospital

Immune System Diseases

Italy

20/05/2026

Phase I

SAR447971 first-in-human study

2026-525333-22-00Hidradenitis

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Netherlands

20/05/2026

Phase III

A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa

2025-523259-72-00Hidradenitis Suppurativa (HS)

Novartis Pharma AG

Immune System Diseases

Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Denmark

20/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

2025-523087-20-00Duchenne muscular dystrophy

DrugAOC 1044

Avidity Biosciences Inc.

Musculoskeletal Diseases

Italy, Germany, France, Spain, Belgium, Poland, Netherlands

20/05/2026

Phase IV

Erdosteine effect on oxidative stress, inflammatory response and immune modulation in patients with COPD. A single center, open label, double arm, controlled, 4-week, explorative, ex vivo study.

2025-524821-42-00COPD

ASST Fatebenefratelli Sacco

Respiratory Tract Diseases

Italy

20/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

2025-524005-32-00Rheumatoid arthritis

Elevara Medicines Limited

Immune System Diseases

Czechia, Bulgaria, Hungary, Netherlands, Poland, Spain

19/05/2026

Phase I

An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

2025-524060-38-00Active Ulcerative Colitis (UC)

F. Hoffmann-La Roche AG

Digestive System Diseases

Germany, Poland, Belgium

19/05/2026

Phase II

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis

2025-523464-20-00Moderate to Severe Atopic Dermatitis

Janssen Cilag International

Immune System Diseases

Germany, Poland

19/05/2026

Phase III

Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial

2025-524408-30-01Metastatic hormone-sensitive prostate cancer

DrugApalutamide

Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Neoplasms

Spain, Germany, France, Portugal, Italy

19/05/2026

Phase III

A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)

2025-521632-12-00Patients on Factor Xa inhibitor treatment needing an urgent…

VarmX B.V.

Hemic and Lymphatic Diseases

Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania

19/05/2026

Phase II

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

2025-523425-17-00Proteinuric kidney diseases

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Nutritional and Metabolic Diseases

Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia

19/05/2026

Phase II

Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations

2025-523567-38-00locally advanced or metastatic NSCLC

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Germany, France, Spain

19/05/2026

Phase II

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma

2025-524140-35-00Neuroblastoma or ganglioneuroblastoma (nodular or intermixe…

Fundacio Sant Joan De Deu

Neoplasms

Spain

19/05/2026

Phase II

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

2024-519246-75-01Patients With Muscle-Invasive Bladder Cancer

AstraZeneca AB

Neoplasms

Italy, Spain, France, Netherlands

19/05/2026

Phase III

A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming. "BAZOOKA_221"

2025-524765-24-00Rabies infection/prophylaxis

Institute Of Tropical Medicine

Virus Diseases

Belgium

19/05/2026

Phase II

A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone

2025-524308-31-00Acute myeloid leukemia

DrugsAzacitidine·Venetoclax

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe

Neoplasms

Italy, Spain

19/05/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

2025-523735-19-00Metastatic Microsatellite Stable Colorectal Cancer

DrugsINCA33890·Calcium folinate·Fluorouracil·Oxaliplatin

Incyte Corp.

Neoplasms

Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy

19/05/2026

Phase III

Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).

2025-524377-16-00Recurrent Non-Complicated Urinary Tract Infections (rUTIs).

DrugsFosfomycin·Pivmecillinam·Nitrofurantoin

Inmunotek S.L.

Bacterial Infections and Mycoses

Portugal

19/05/2026

Phase III

Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).

2025-524475-23-00Neisseria gonorrhoeae Infections

DrugCeftriaxone

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

18/05/2026

Phase I

A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease

2024-517310-15-00Parkinson's Disease

Mission Therapeutics Limited

Nervous System Diseases

Germany, Netherlands, France

18/05/2026

Phase IV

A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative

2025-525005-20-00Male Infertility

DrugGonal-F

Martin-Luther-Universitaet Halle-Wittenberg

Reproductive and Urinary Physiological Phenomena

Italy, Spain, Germany

18/05/2026

Phase III

EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections

2025-524697-42-00Pleural infections

DrugsCefotaxime·Dornase Alfa·Clindamycin·Alteplase

Centre Hospitalier Universitaire Amiens Picardie

Respiratory Tract Diseases

France

18/05/2026

Phase II

INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an “add-on” Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial

2025-524093-41-00Incremental Haemodialysis

Centre Hospitalier Le Mans

Nutritional and Metabolic Diseases

France

18/05/2026

Phase I

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

2026-525590-40-00human immunodeficiency virus (HIV)

Viiv Healthcare UK Limited

Immune System Diseases

Netherlands

18/05/2026

Phase II

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.

2025-521816-20-00Exocrine Pancreatic Insufficiency

DrugZenpep

Aimmune Nestle Health Science US R&D LLC

Nutritional and Metabolic Diseases

Poland, Hungary, Spain, Bulgaria, Italy

18/05/2026

Phase III

Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Blomia tropicalis

2025-522773-12-00Aetiological treatment of moderate-to-severe allergic rhini…

Inmunotek S.L.

Immune System Diseases

Spain

18/05/2026

Phase II

Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV

2025-524978-42-00Asymptomatic anal LGV infection

DrugDoxycycline

Centre Hospitalier Universitaire De Bordeaux

Bacterial Infections and Mycoses

France

18/05/2026

Phase I/II

mRNA Therapy to restore lymphatic flow in secondary lymphedema

2024-520149-22-00Lymphedema

Centre Hospitalier Universitaire De Toulouse

Hemic and Lymphatic Diseases

France

18/05/2026

Phase IV

Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”

2025-524942-87-00Gastroenteropancreatic neuroendocrine tumors

Centre De Lutte Contre Le Cancer Eugene Marquis

Neoplasms

France

18/05/2026

Phase I/II

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer

2025-524090-16-00Relapsed/Refractory Small Cell Lung Cancer

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Italy, Spain, Romania

18/05/2026

Phase II

TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)

2025-522431-34-00Advanced pancreatic cancer

DrugsPemigatinib·Vismodegib·Larotrectinib·Erlotinib

Region Hovedstaden

Neoplasms

Denmark

18/05/2026

Phase II

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

2024-518871-74-00Locally Advanced or Metastatic Solid Tumours that harbour M…

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, France, Denmark

18/05/2026

Phase II

THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation

2025-524541-27-00Hyperinflammation, Sepsis

DrugAnakinra

Prinses Maxima Centrum voor Kinderoncologie B.V.

Immune System Diseases

Netherlands

18/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

2025-524316-11-00Primary Progressive Multiple Sclerosis (PPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary

18/05/2026

Phase II

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

2025-522138-29-00Philadelphia positive Chronic Myeloid leukemia in Chronic P…

Novartis Pharma AG

Neoplasms

Spain, France, Germany, Poland, Italy, Netherlands, Greece, Hungary

18/05/2026

Phase IV

The effect of beta-blockers on how you feel and recover after a heart attack when your heart is still pumping well

2026-525475-96-00Myocardial infarction without reduced ejection fraction

UZ Leuven

Cardiovascular Diseases

Belgium

18/05/2026

Phase IV

A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.

2025-524289-56-00Asthma

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Germany, Romania, Italy, Bulgaria, Poland, Slovakia, Spain, France

18/05/2026

Phase I

A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors

2025-524192-24-00advanced refractory solid tumors

Samsung Bioepis Co. Ltd.

Neoplasms

Spain

18/05/2026

Phase II

SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.

2025-525091-29-00Kidney Transplant Recipient

DrugBelatacept

Medical University Of Vienna

Surgical Procedures, Operative

Austria

17/05/2026

Phase III

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%

2025-523586-18-00Non-Small Cell Lung Cancer

DrugPembrolizumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia

15/05/2026

Phase I/II

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

2025-525127-27-00Generalized Myasthenia Gravis

Aurinia Pharmaceuticals Inc.

Immune System Diseases

Poland, Spain, Denmark

15/05/2026

Phase I

A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

2026-525543-32-00Recurrent glioblastoma

Oncopeptides AB

Nervous System Diseases

Norway

15/05/2026

Phase I/II

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

2026-525248-13-00Advanced Solid Tumors

Eikon Therapeutics Inc.

Neoplasms

France, Spain, Norway, Italy, Germany, Austria, Poland, Finland, Belgium, Denmark, Portugal

15/05/2026

Phase I

Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

2025-524052-58-00Healthy Overweight or Obese

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Netherlands

15/05/2026

Phase III

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)

2024-516734-35-00triple-negative early breast cancer

DrugsSacituzumab Govitecan·Pembrolizumab

WSG Women's Cancer Study Group GmbH

Neoplasms

Germany, Poland

15/05/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

2024-520446-31-00Participants with overweight or obesity, and type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Germany, Croatia, Portugal, Hungary, Bulgaria, Romania, Poland

15/05/2026

Phase II

A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

2025-521976-80-00Relapsed or Refractory Multiple Myeloma (RRMM)

Janssen Cilag International

Neoplasms

Poland, Italy

14/05/2026

Phase III

2025-522771-28-00Aetiological treatment of moderate-to-severe allergic rhini…

Inmunotek S.L.

Immune System Diseases

Spain

14/05/2026

Phase III

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

2025-523389-26-00Relapsed/refractory primary central nervous system lymphoma

Deciphera Pharmaceuticals Inc.

Nervous System Diseases

Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary

14/05/2026

Phase III

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

2025-524810-28-00Acute Promyelocytic Leukemia

DrugArsenic Trioxide

Quetzal Therapeutics LLC

Neoplasms

Germany, Poland, Spain, Romania, Italy, France

13/05/2026

Phase II

Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy

2025-524317-88-00Multiple System Atrophy

Alterity Therapeutics Limited

Nervous System Diseases

France

13/05/2026

Phase I

A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167

2026-526096-31-00Chronic Heart Failure

Corteria Pharmaceuticals

Cardiovascular Diseases

Netherlands

13/05/2026

Phase I/II

Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN

2024-517130-17-00FLT3-mutated Acute Myeloid Leukemia

DrugVenetoclax

Centre Hospitalier Universitaire De Bordeaux

Neoplasms

France

13/05/2026

Phase IV

Reproductive outcomes with letrozole co-treatment during ovarian stimulation in women with endometriosis undergoing IVF/ICSI: a randomised, multicentre, parallel group pragmatic trial

2025-524995-53-00Women with endometriosis undergoing IVF/ICSI

UZ Brussel

Reproductive and Urinary Physiological Phenomena

Belgium

13/05/2026

Phase III

A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.

2025-523869-22-00advanced or metastatic extrapulmonary neuroendocrine carcin…

DrugsObrixtamig·Tocilizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway

13/05/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis

2025-523404-74-00Prurigo Nodularis

Innocare Pharma Inc.

Skin and Connective Tissue Diseases

Belgium, Poland, Germany, France, Austria

13/05/2026

Phase IV

A phase IV proof-of-concept study to assess the safety and efficacy of Maribavir to inhibit high Virus Epstein-Barr (VEB) replication among young adult kidney transplant recipie

2025-524786-25-00Transplant patients with high recurrent Epstein-Barr infect…

DrugMaribavir

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Virus Diseases

Spain

13/05/2026

Phase III

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)

2025-524214-28-00Heterozygous Familial Hypercholesterolemia

DrugLerodalcibep

LIB Therapeutics Inc.

Nutritional and Metabolic Diseases

Norway

13/05/2026

Phase II

SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds

2025-525083-14-00Scar formation following surgical wounds

DrugVerteporfin

Odense University Hospital

Therapeutics

Denmark

13/05/2026

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

2025-523106-32-00Obesity or Overweight and Type 2 Diabetes

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy

13/05/2026

Phase III

IMMUNOTIME « EVALUATION OF THE EFFECT OF TIME OF ADMINISTRATION ON THE ACTIVITY ON FIRST LINE OF PEMBROLIZUMAB IN ASSOCIATION WITH CARBOPLATIN PEMETREXED IN METASTATIC NON-SQUAMOUS LUNG CANCER. A RANDOMISED MULTICENTER PHASE III TRIAL»

2025-521891-78-00Adult patients with stage IV non squamous non-small cell lu…

DrugsPemetrexed·Carboplatin·Pembrolizumab

Assistance Publique Hopitaux De Paris

Neoplasms

France

12/05/2026

Phase I

A clinical trial of MK-1824 in healthy participants (MK-1824-001)

2026-525748-14-00Heart failure with preserved ejection fraction

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Belgium

12/05/2026

Phase III

Effect of vasopressin versus norepinephrine on post-operative mean pulmonary arterial pressure following pulmonary endarterectomy surgery, a randomized open label trial

2025-525153-39-00Chronic thromboembolic pulmonary hypertension

Fondation Hopital Saint Joseph

Respiratory Tract Diseases

France

12/05/2026

Phase II

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

2026-525213-31-00Esophageal squamous cell carcinoma

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Germany, France, Norway

12/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

2025-521950-41-00severe uncontrolled asthma

DrugGB-0895

Generate Biomedicines Inc.

Respiratory Tract Diseases

Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands, Croatia, Germany, Greece, Czechia

12/05/2026

Phase III

DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.

2025-520565-51-00small cell lung cancer

DrugsObrixtamig·Tocilizumab·Atezolizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary

12/05/2026

Phase III

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

2025-522586-30-00Psoriatic Arthritis

DrugZasocitinib

Takeda Development Center Americas Inc.

Musculoskeletal Diseases

Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy

12/05/2026

Phase II

Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025

2025-524077-16-00metastatic urothelial carcinoma

DrugAvelumab

G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Neoplasms

Italy

12/05/2026

Phase II

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

2025-523895-22-00Non-small cell lung cancer (NSCLC), Cervical cancer (CC), M…

DrugsBNT324·Pumitamig

Dualitybio Inc.

Neoplasms

Italy, Poland, France, Spain, Germany

12/05/2026

Phase III

MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease

2025-521331-36-00Patient with stabilized SSc-ILD (as defined by a decline of…

DrugRituximab

Assistance Publique Hopitaux De Paris

Skin and Connective Tissue Diseases

France

11/05/2026

Phase III

A randomized controlled non-inferiority trial comparing 7 versus 14 days of ciprofloxacin for male urinary tract infections with systemic involvement.

2025-524703-76-00Urinary tract infection with systemic involvement (UTI: def…

UZ Brussel

Bacterial Infections and Mycoses

Belgium

11/05/2026

Phase II

Evaluation of hANP for prevention of acute kidney injury after cardiac surgery: A two-part randomized controlled trial with open-label extension in children aged 0–12 months.

2025-524069-26-00Acute kidney injury (AKI) occurring in newborns and infants…

Vaestra Goetalandsregionen

Therapeutics

Sweden

11/05/2026

Phase I

A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

2025-522744-40-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Netherlands, Denmark

11/05/2026

Phase IV

PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

2025-522883-34-00Metastatic cervical cancer

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

11/05/2026

Phase III

The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma

2026-525608-85-00Paraffin Oil Induced Granulomatous Disease

DrugsLosartan·Dapagliflozin

Region Hovedstaden

Musculoskeletal Diseases

Denmark

11/05/2026

Phase I

A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D

2025-524921-42-00Type 2 Diabetes, Obesity

Gubra A/S

Nutritional and Metabolic Diseases

Germany

11/05/2026

Phase I

A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults

2025-523562-24-00Heathy volunteer trial

Regeneron Pharmaceuticals Inc.

Not possible to specify

Belgium

11/05/2026

Phase I

A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)

2025-520631-17-00Huntington’s Disease Gene Expansion Carriers

F. Hoffmann-La Roche AG

Nervous System Diseases

Italy, Poland, Denmark, Germany, Portugal, Spain

11/05/2026

Phase III

A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)

2025-524265-24-00Dyslipidemia at High to Very High Cardiovascular Risk

A. Menarini International Licensing S.A.

Hemic and Lymphatic Diseases

Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany

11/05/2026

Phase I

A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

2026-525350-11-00Immune Thrombocytopenia Purpura

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Germany

11/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")

2025-522854-37-00Prevention of a Major infection in patients with Hypogammag…

Octapharma Pharmazeutika Produktionsgesellschaft mbH

Immune System Diseases

Czechia, Lithuania, Greece, Poland, Germany, Latvia, Bulgaria, Italy

11/05/2026

Phase III

J5E-MC-JZXB - FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

2025-522255-25-00Neoplasm Metastasis, Fallopian Tube Neoplasms, Ovarian Neop…

Eli Lilly & Co.

Neoplasms

Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany

11/05/2026

Phase III

A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies

2025-522983-33-00Chronic rhinosinusitis with nasal polyps

DrugItepekimab

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland

11/05/2026

Phase III

A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)

2025-523134-28-00ABC borderline resectable pancreatic cancer

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

11/05/2026

Phase I

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

2025-521173-13-00Advanced Solid Tumors

Daiichi Sankyo Inc.

Neoplasms

France, Spain

08/05/2026

Phase II

FINACCESS - Finnish National Study for Early Access to Cancer Therapies

2025-524769-26-00Cancer

HUS-yhtymae

Neoplasms

Finland

08/05/2026

Phase II

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

2025-524435-39-00Localized Scleroderma

DrugLebrikizumab

Charite Universitaetsmedizin Berlin KöR

Skin and Connective Tissue Diseases

Germany

08/05/2026

Phase I/II

A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies

2025-523399-22-00Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Car…

DrugsREGN10597·Cemiplimab

Regeneron Pharmaceuticals Inc.

Neoplasms

Italy, Spain, Germany, France

08/05/2026

Phase II

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis

2025-523797-17-00Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics Inc.

Skin and Connective Tissue Diseases

Germany, Spain

08/05/2026

Phase III

A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.

2025-522618-22-00Treatment of moderate to severe glabellar lines

Ipsen Innovation

Physical Phenomena

France, Germany

07/05/2026

Phase I/II

LAMP-COVID: Locating Amyloid-containing Microclots with total-body PET in post-COVID syndrome

2025-522348-42-00post-COVID syndrome (long COVID)

Amsterdam UMC Stichting

Virus Diseases

Netherlands

07/05/2026

Phase III

2025-523104-71-00Obesity or Overweight Without Type 2 Diabetes

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain

07/05/2026

Phase III

Optimizing Aspirin Use for Preeclampsia Prevention

2025-524646-94-00Obstetrics – Preeclampsia

DrugAcetylsalicylic acid

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Not possible to specify

Spain

07/05/2026

Phase II

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)

2026-525214-62-00Localised dMMR Colon Cancer

DrugPembrolizumab

Region Sjaelland

Digestive System Diseases

Denmark

07/05/2026

Phase II

A prospective, multinational, multicenter, randomized, sequential, double-blind, placebo-controlled, phase 2a clinical study to assess the safety and pharmacokinetics (PK) of OMN6 in hospital-acquired bacterial pneumonia (HABP) or ventilated-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).

2025-524200-29-00Hospital-acquired bacterial pneumonia or ventilated-associa…

Omnix Medical Ltd.

Respiratory Tract Diseases

Italy, Hungary, Greece

06/05/2026

Phase I

A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

2025-525073-37-00Autosomal Dominant Polycystic Kidney Disease

Glaxosmithkline Research & Development Limited

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

06/05/2026

Phase I

PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

2025-523641-10-00Healthy / hepatic impaired volunteers only study to assess …

Zealand Pharma A/S

Not possible to specify

Slovakia, Poland

06/05/2026

Phase II

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Trial Evaluating the Effects of Two Dosing Regimens of Nolasiban on Uterine Contractility and Endocrine Parameters

2025-524896-22-00Women with an indication for IVF/ICSI

ReproNovo ApS

Female Urogenital Diseases and Pregnancy Complications

Spain

06/05/2026

Phase I

A clinical trial of MK-4605 in healthy participants (MK-4605-001)

2026-525627-24-00Dementia

Merck Sharp & Dohme LLC

Nervous System Diseases

Belgium

06/05/2026

Phase II

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

2025-524843-11-00Non-Small Cell Lung Cancer

AstraZeneca AB

Neoplasms

France, Italy, Spain

06/05/2026

Phase IV

Colchicine Assessment of Low-grade Inflammation and Biomarker Response in Atherosclerosis with Targeted Evaluation

2026-525547-32-01Ischemic Heart Disease, Coronary Artery Disease, Chronic Co…

Region Hovedstaden

Cardiovascular Diseases

Denmark

06/05/2026

Phase I/II

Single-centre, randomised, double-blind, split-face comparative design clinical trial to evaluate the efficacy and safety of the topical formulation with 4% hydroquinone and 0,025% tretinoin versus the formulation with 4% hydroquinone in patients with facial melasma

2025-521806-16-00facial melasma

Mesoestetic Pharma Group S.L.

Skin and Connective Tissue Diseases

Spain

05/05/2026

Phase I

Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

2025-522888-15-00Small Cell Lung Cancer

Amgen Inc.

Neoplasms

Spain, Germany, Poland, Belgium, France

05/05/2026

Phase II

A Phase II, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors (eVOLVE-02)

2025-523947-36-00Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomi…

AstraZeneca AB

Neoplasms

Italy, Germany

05/05/2026

Phase IV

Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)

2025-524264-38-00Infectious diseases

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Not possible to specify

Spain

05/05/2026

Phase I

An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of food and effect of apple sauce on bioavailability of the Test product (Bupropion Hydrochloride Extended Release Capsules 150 mg, manufactured by Sun Pharmaceutical Industries Limited, India) in healthy, adult, human subjects.

2025-523411-11-00Seasonal affective disorder, Major depressive disorder

Sun Pharmaceutical Industries Limited

Mental Disorders

Romania

05/05/2026

Phase I

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropion Hydrochloride Extended Release Capsules 150 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with WELLBUTRIN XL (Bupropion hydrochloride) extended release tablets 300 mg, Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA. Manufactured by: Bausch Health Companies, Inc. Steinbach, MB R5G 1Z7, Canada, in healthy, adult, human subjects under fasting condition.

2025-523410-84-00Seasonal affective disorder, Major depressive disorder

Sun Pharmaceutical Industries Limited

Mental Disorders

Romania

05/05/2026

Phase I/II

PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study)

2025-524613-89-00HER2 positive advanced breast cancer

Medica Scientia Innovation Research S.L.

Neoplasms

Spain

05/05/2026

Phase I

Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects

2025-524376-36-00short-term treatment of insomnia

Orion Corporation

Nervous System Diseases

Czechia

05/05/2026

Phase III

Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

2025-523443-35-00Persistent Corneal Epithelial Defect (PCED)

Dompe' Farmaceutici S.p.A.

Eye Diseases

Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France

05/05/2026

Phase II

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

2025-524001-33-00Graves’ Disease

Immunovant Sciences GmbH

Immune System Diseases

Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia

05/05/2026

Phase I

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec® (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo – SP, CNPJ: 56.994.502/0001-30, Brazilian Industry, in healthy adult, human subjects under fed condition.

2025-524935-38-00(Ph+) Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemi…

Sun Pharmaceutical Industries Limited

Neoplasms

Romania

05/05/2026

Phase I

A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra

2026-525752-29-00bioavailability trial with healthy participants, therapeuti…

Farco-Pharma GmbH

Anesthesia and Analgesia

Germany

05/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes

2025-523486-17-00Obesity

DrugRibupatide

Kailera Therapeutics Inc.

Nutritional and Metabolic Diseases

Bulgaria, Hungary, Spain, Germany, Czechia, Poland

05/05/2026

Phase III

A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia

2025-523811-12-00Achondroplasia

DrugVosoritide

Biomarin Pharmaceutical Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Poland, Italy, Romania, France, Norway, Netherlands

05/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

2025-523552-31-00Systemic Lupus Erythematosus

Janssen Cilag International

Immune System Diseases

Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland

05/05/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)

2024-520440-42-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Denmark, France, Germany, Belgium

04/05/2026

Phase II

A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration

2025-523704-77-00Geographic atrophy secondary to age-related macular degener…

Novartis Pharma AG

Eye Diseases

Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France

04/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes

2025-523510-87-00Obesity

DrugRibupatide

Kailera Therapeutics Inc.

Nutritional and Metabolic Diseases

Hungary, Poland, Bulgaria, Germany, Czechia, Spain

04/05/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)

2024-520441-23-00Overweight or obesity, and type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Italy, Croatia, Hungary, Slovakia, Romania

04/05/2026

Phase II

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

2025-523488-39-00Systemic lupus erythematosus

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Immune System Diseases

Bulgaria, Romania, Germany, Spain, Hungary, Poland, Croatia, Netherlands

04/05/2026

Phase III

Modafinil for debilitating fatigue in quiescent inflammatory bowel disease: a multicentre, randomised, double-blind, placebo-controlled, clinical trial (MODIFI-IBD trial)

2026-525163-41-00Inflammatory bowel disease, Fatigue

Radboud universitair medisch centrum Stichting

Digestive System Diseases

Netherlands

04/05/2026

Phase IV

Efficacy and Safety of Daridorexant in Patients with Major Depressive Disorder (MDD) and Insomnia: Double-blind, randomized, controlled trial

2025-524794-16-00Patients with major depressive episode and moderate to seve…

Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Mental Disorders

Spain

04/05/2026

Phase II

Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach

2025-521690-14-00Major depressive disorder

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Mental Disorders

Spain

04/05/2026

Phase III

A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy

2024-519638-22-00IgA nephropathy

Novartis Pharma AG

Immune System Diseases

Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain

04/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)

2024-516993-31-00Renal Cell Carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece

04/05/2026

Phase I

CD5CAR-NK cells for refractory invasive mold disease

2025-524638-24-00refractory invasive mold disease

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Bacterial Infections and Mycoses

Spain

04/05/2026

Phase II

Staphylococcus aureus Network Adaptive Platform trial (SNAP)

2025-521388-11-00Staphylococcus aureus bacteraemia

Fundacion Para La Gestion De La Investigacion En Salud De Sevilla

Bacterial Infections and Mycoses

Spain

04/05/2026

Phase I

An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging pathological alpha-synuclein deposition in the brains of patients with Parkinson’s disease (PD) or Multiple System Atrophy (MSA) compared to age-matched healthy controls (AMHC)

2023-506965-72-00Parkinson Disease, Multiple System Atrophy, Healthy Volunte…

Modag GmbH

Not possible to specify

Germany

04/05/2026

Phase I

A PHASE 1, OPEN-LABEL, SINGLE-DOSE MASS BALANCE AND METABOLITE PROFILING STUDY OF 14C-LABELED IZICOPAN (INF904) IN HEALTHY MALE PARTICIPANTS

2026-525517-31-00Not applicable, healthy volunteers

InflaRx GmbH

Not possible to specify

Netherlands

01/05/2026

Phase IV

PHASE IV, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY ON THE PAIN-RELIEF EFFECT OF BENZYDAMINE HYDROCHLORIDE LOZENGES 3 MG MINT TASTE (TANTUM VERDE) IN NON STREPTOCOCCAL PHARYNGOTONSILLITIS IN PEDIATRIC AGE (6-11 YEARS OLD).

2025-521526-15-00NON STREPTOCOCCAL PHARYNGOTONSILLITIS

Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

Respiratory Tract Diseases

Italy

30/04/2026

Phase IV

Multicenter clinical trial on the effectiveness and safety of outpatient treatment of acute uncomplicated diverticulitis without antibiotics versus antibiotic treatment. ADIANA Trial.

2025-523121-17-00Diverticular disease of the intestine,

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Digestive System Diseases

Spain

30/04/2026

Phase II

"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"

2025-524434-25-00gastric cancer

Drug[68Ga]Ga-FAPI-46

Centre Hospitalier Universitaire De Bordeaux

Neoplasms

France

30/04/2026

Phase II

Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE

2025-524511-36-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

30/04/2026

Phase IV

Switching to Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Sustained Remission: A Multicenter Randomized Controlled Trial (IDEA).

2025-524675-23-00Ulcerative Colitis

Grupo Espanol De Trabajo En Enfermedad De Crohn y Colitis Ulcerosa

Digestive System Diseases

Spain

30/04/2026

Phase I

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis

2025-524205-32-00Atopic Dermatits

Regeneron Pharmaceuticals Inc.

Skin and Connective Tissue Diseases

Belgium, Czechia, Germany, Poland

30/04/2026

Phase I

Study to Learn How Safe EV25 is and the Amount of EV25 in the Body Over a Period of Time, When Given as a Single Dose to Adult Healthy People [CCI]

2026-525176-26-00Influenza

Eradivir Inc.

Virus Diseases

Belgium

30/04/2026

Phase I

A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.

2026-525575-22-00Psoriasis

Klear Bio Inc.

Immune System Diseases

Netherlands

30/04/2026

Phase I

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

2025-524267-20-00Adjuvant treatment of BRAF V600E or V600K mutation-positive…

Sun Pharmaceutical Industries Limited

Neoplasms

Romania

30/04/2026

Phase I

A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

2026-525619-15-00Bacterial Infection

Centauri Therapeutics Limited

Bacterial Infections and Mycoses

Netherlands

30/04/2026

Phase III

A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors

2025-523750-14-00refractory hypotension in distributive shock

Paion Pharma GmbH

Cardiovascular Diseases

Italy, Germany, France, Spain

30/04/2026

Phase I

A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION, INCLUDING THE MASS BALANCE, OF A SINGLE ORAL DOSE OF [14C]-VAFIDEMSTAT IN HEALTHY MALE PARTICIPANTS

2025-524832-20-00Healthy volunteers

Oryzon Genomics S.A.

Not possible to specify

Netherlands

30/04/2026

Phase II

GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery

2024-514089-37-00Patients with pulmonary metastasis from any primary tumour,…

The University Of Birmingham

Neoplasms

Netherlands

30/04/2026

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

2025-520997-21-00Psoriatic arthritis

Merck Sharp & Dohme LLC

Musculoskeletal Diseases

Poland, Germany, Spain

30/04/2026

Phase III

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)

2025-523285-25-00Relapsed or Refractory Multiple Myeloma

DrugsAZD0120·Carfilzomib·Pomalidomide·Bortezomib

AstraZeneca AB

Neoplasms

Norway, Poland, Spain, Germany, France, Italy

30/04/2026

Phase I

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors

2025-524857-15-00Advanced Solid Tumors

BeOne Medicines I GmbH

Neoplasms

Spain

30/04/2026

Phase IV

EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales ("RAPID")

2024-520067-13-00Bloodstream Infection, Ventilator Associated Pneumonia and …

National University Of Singapore

Bacterial Infections and Mycoses

Italy, Greece

29/04/2026

Phase I

Effect of NBI-921355 on corticospinal excitability in healthy participants

2025-524134-26-00Epilepsy

Neurocrine Biosciences Inc.

Nervous System Diseases

Netherlands

29/04/2026

Phase III

An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery

2025-525053-39-00Coronary artery disease

EBI Anti Sepsis B.V.

Cardiovascular Diseases

Belgium, Netherlands

29/04/2026

Phase I/II

A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis

2025-524719-35-00Ulcerative Colitis

Mage Biologics Inc.

Digestive System Diseases

Poland

29/04/2026

Phase III

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes

2025-523511-11-00Obesity

Kailera Therapeutics Inc.

Nutritional and Metabolic Diseases

Poland, Bulgaria

29/04/2026

Phase I

Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.

2025-522468-34-00Androgenetic alopecia

Bioresearch Pharma S.A.

Skin and Connective Tissue Diseases

Poland

29/04/2026

Phase III

THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL

2025-525006-37-00Infection and sepsis

DrugMeropenem

Elliniko Institouto Meletis Tis Sipsis

Pathological Conditions, Signs and Symptoms

Greece

29/04/2026

Phase III

HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma

2025-524876-43-00relapsed/refractory multiple myeloma

DrugsElotuzumab·Carfilzomib·Pomalidomide·Bortezomib

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

29/04/2026

Phase I

Bioequivalence clinical trial of two formulations of canagliflozin

2026-525944-14-00Healthy volunteers

Laboratorios Normon S.A.

Not possible to specify

Spain

29/04/2026

Phase I

Bioequivalence clinical trial of two formulations of loperamide.

2026-525278-20-00Healthy volunteers

Laboratorios Normon S.A.

Not possible to specify

Spain

29/04/2026

Phase I

Pilot, randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fasting conditions in healthy male volunteers.

2026-525930-47-00Healthy volunteers

Farmalider S.A.

Not possible to specify

Spain

29/04/2026

Phase II

A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)

2025-524058-32-00Schizophrenia

Novartis Pharma AG

Mental Disorders

Bulgaria

29/04/2026

Phase I/II

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy

2025-521145-24-01Active Idiopathic Inflammatory Myopathy including dermatomy…

DrugEndoxan

Cabaletta Bio Inc.

Immune System Diseases

Italy, Spain, Germany

28/04/2026

Phase III

A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression

2025-522872-10-00Depressive episodes associated with Bipolar disorder I or I…

Xenon Pharmaceuticals Inc.

Mental Disorders

Bulgaria, Germany, France, Spain

28/04/2026

Phase II

Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study

2025-523448-10-00Gvhd Resistant to ruxolitinib and steroids

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Hemic and Lymphatic Diseases

Italy

28/04/2026

Phase I

A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers

2026-526135-18-00Idiopathic pulmonary fibrosis

Vicore Pharma AB

Respiratory Tract Diseases

Sweden

28/04/2026

Phase I

AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors

2025-524056-63-00microsatellite instability high/mismatch repair deficient (…

Amgen Inc.

Neoplasms

Spain, France, Belgium

28/04/2026

Phase III

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.

2024-520218-23-00Pulmonary Arterial Hypertension

Inhibikase Therapeutics Inc.

Cardiovascular Diseases

Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania

28/04/2026

Phase II

A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

2025-521983-36-00Colorectal cancer (CRC), gastric cancer (GC), pancreatic du…

Blue Earth Diagnostics Ireland Limited

Neoplasms

Netherlands, Italy

28/04/2026

Phase III

CIRCULATE III - Tailoring the decision for adjuvant chemotherapy using circulating tumour DNA, in patients with stage III colorectal cancer

2025-521045-24-00Stage III colorectal cancer

Unicancer

Neoplasms

France, Sweden

28/04/2026

Phase III

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

2025-524160-38-00Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dM…

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark

28/04/2026

Phase III

ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial

2025-520842-31-00Population of study participants Pregnant women with PPROM …

DrugsCeftriaxone·Azithromycin·Amoxicillin

Assistance Publique Hopitaux De Paris

Female Urogenital Diseases and Pregnancy Complications

France

28/04/2026

Phase II

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

2025-521154-42-00Sickle Cell Disease

CSL Behring LLC

Hemic and Lymphatic Diseases

Belgium, Netherlands, France, Italy

28/04/2026

Phase I

A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

2025-525125-12-00Migraine with or without aura

Pfizer Inc.

Nervous System Diseases

Belgium

28/04/2026

Phase IV

MERCURE study: MEthotrexate in ReCurrent dVIN

2025-524373-17-00dVIN caused by Lichen Sclerosus

Amsterdam UMC Stichting

Skin and Connective Tissue Diseases

Netherlands

28/04/2026

Phase II

Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)

2025-521967-11-00The study population includes adult ICU patients with a hos…

DrugNaCl

Assistance Publique Hopitaux De Paris

Mental Disorders

France

28/04/2026

Phase III

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

2025-522750-39-00Erosive esophagitis (EE) due to gastroesophageal reflux dis…

Cinclus Pharma Holding AB (publ)

Digestive System Diseases

Hungary, Germany, Romania, Bulgaria, Czechia, Poland

28/04/2026

Phase II

A phase II, double-blinded, placebo-controlled, clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder.

2024-510873-11-00Borderline personality disorder

Apurano Pharmaceuticals GmbH

Mental Disorders

Germany

28/04/2026

Phase I

Safety of stem cells in treatmemt of retinal diseases.

2023-503573-38-00Retinal degenerative diseases

Bioinova a.s.

Eye Diseases

Czechia

28/04/2026

Phase III

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

2025-522957-20-00Myotonic Dystrophy Type 1

Dyne Therapeutics Inc.

Nervous System Diseases

Netherlands, Spain, Italy, Denmark, Germany, Belgium, France

28/04/2026

Phase III

Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity

2023-509176-42-00Obesity and T2D

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria

28/04/2026

Phase III

A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral mucositis in head and neck cancer

2025-524386-24-00Head and neck cancer, Oral mucositis

OncoZenge AB

Anesthesia and Analgesia

Germany, Denmark, Norway, Sweden

28/04/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)

2023-508047-40-00Ovarian cancer

Merck Sharp & Dohme LLC

Neoplasms

Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden

28/04/2026

Phase III

Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome

2025-522552-20-00Lennox-Gastaut Syndrome

Epygenix Therapeutics Inc.

Nervous System Diseases

Italy, Spain, Hungary, Romania, Czechia, Poland

28/04/2026

Phase III

Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia

2024-517388-22-00Agitation in Alzheimer's Disease Dementia

Exciva GmbH

Nervous System Diseases

Italy, Slovakia, Spain, Poland, Czechia, Germany

28/04/2026

Phase I

A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

2025-524135-39-00Healthy volunteer trial

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

28/04/2026

Phase III

A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)

2023-504135-40-00Classical Homocystinuria

Travere Therapeutics Inc.

Nutritional and Metabolic Diseases

Belgium, Ireland, Spain, Italy, Germany, France, Portugal, Poland

27/04/2026

Phase II

A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis

2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania

27/04/2026

Phase III

Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).

2025-523804-62-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands

27/04/2026

Phase III

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

2025-523495-23-00Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines Inc.

Digestive System Diseases

France, Spain, Italy, Germany

27/04/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)

2024-519298-21-00Cancer-Associated Thrombosis (CAT).

DrugCenvacibart

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain

27/04/2026

Phase III

SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years

2024-511114-20-00Craniopharyngioma

DrugSemaglutide

Centre Hospitalier Universitaire D'Angers

Nervous System Diseases

France

27/04/2026

Phase I

A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function

2025-521647-20-00hepatic impairment

Novo Nordisk A/S

Not possible to specify

Slovakia

27/04/2026

Phase III

Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients with chronic venous insufficiency

2025-524103-69-00Chronic Venous Insufficiency

VeriGraft AB

Cardiovascular Diseases

Spain

27/04/2026

Phase IV

A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

2025-522362-78-00severely active ulcerative colitis (US) and CD (Crohn’s dis…

DrugMirikizumab

Eli Lilly & Co.

Immune System Diseases

Spain, Denmark, Germany, Italy, Poland

27/04/2026

Phase II

A randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and quality of life outcomes of Vi-Siblin in patients with low anterior resection syndrome following rectal cancer surgery.

2024-514541-11-00Low anterior resection syndrome after low anterior resectio…

Sykehuset Telemark HF

Digestive System Diseases

Norway

27/04/2026

Phase II

Methylphenidate for Early Awakening in Coma (MEAWAKE)

2025-524937-19-00Coma due to acute brain injury

DrugMethylphenidate

Rigshospitalet

Nervous System Diseases

Austria, Denmark, Germany, France

27/04/2026

Phase II

The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab

2024-518858-17-00Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CL…

DrugsAcalabrutinib·Venetoclax

AstraZeneca AB

Neoplasms

Italy, Austria, Spain, Ireland, Czechia, Poland

27/04/2026

Phase I/II

Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer

2025-523972-21-00Extensive-Stage Small Cell Lung Cancer

Fortvita Biologics (USA) Inc.

Respiratory Tract Diseases

Poland, Denmark, Spain

27/04/2026

Phase II

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome

2025-523738-21-00Fragile X Syndrome

Mirum Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain

27/04/2026

Phase I/II

A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

2025-522019-40-00relapsed or refractory BCR::ABL1-positive (Philadelphia pos…

DrugsAsciminib·Hydrocortisone·Blinatumomab·Cytarabine

Novartis Pharma AG

Neoplasms

Italy, Spain, Germany, Netherlands, France, Denmark, Czechia

27/04/2026

Phase I

Relative bioavailability and effect of food study with GLPG3667 in healthy subjects

2026-525706-35-00inflammatory and autoimmune diseases

Galapagos

Immune System Diseases

Belgium

27/04/2026

Phase I

A Study of GEN1106 in Participants with Solid Tumors

2025-523760-21-00Metastatic or advanced malignant solid tumors

Genmab A/S

Not possible to specify

Spain

27/04/2026

Phase III

A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 12-Week Trial to Evaluate the Efficacy and Safety of Treatment with K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg

2025-523739-20-00Hypercholesterolemia

Kowa Co. Ltd.

Cardiovascular Diseases

Spain

24/04/2026

Phase II

Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM

2025-524602-15-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

24/04/2026

Phase III

ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial

2025-524122-18-00Septic shock

DrugsNorepinephrine·Hydrocortisone·Midazolam·Propofol

Hospices Civils De Lyon

Not possible to specify

France

24/04/2026

Phase I/II

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies

2025-523774-16-00Advanced malignancies

DrugsPM54·Pembrolizumab

Pharma Mar S.A.

Neoplasms

Spain, France, Italy

24/04/2026

Phase II

Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-MED randomized clinical trial

2024-518120-68-01Paraphilic disorder, Compulsive sexual behavior disorder

DrugsTestosterone·Degarelix

Vaestra Goetalandsregionen

Mental Disorders

Sweden

24/04/2026

Phase II

A randomized phase 2 trial of neoadjuvant pembrolizumab plus belzutifan with or without lenvatinib in patients with localized renal cell carcinoma. The moonlanding trial

2024-519673-18-00Patients with localized renal cell carcinoma

DrugsBelzutifan·Lenvatinib·Pembrolizumab

Vall D Hebron Institute Of Oncology

Neoplasms

Spain

24/04/2026

Phase I

Phase 1b study to assess the safety and tolerability of SR-878 in patients with rheumatoid arthritis

2025-523678-17-00rheumatoid arthritis

SciRhom GmbH

Immune System Diseases

Romania

24/04/2026

Phase I

Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

2026-526102-33-00No medical condition

Laboratorios Cinfa S.A.

Not possible to specify

Czechia

24/04/2026

Phase IV

Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)

2025-523589-26-00Acute heart failure with volume overload

Region Midtjylland

Cardiovascular Diseases

Denmark

24/04/2026

Phase II

Curing HIV: proof of concept randomized clinical trial with Pyrimethamine, Lenalidomide, TOpiramate (PLUTO)

2026-525211-14-00HIV-1

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Virus Diseases

Netherlands

24/04/2026

Phase II

Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.

2025-524255-32-00Cutaneous squamous cell carcinoma (ccSCC)

DrugCemiplimab

Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Neoplasms

Spain

24/04/2026

Phase II

Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial

2025-521836-12-00deep vein thrombosis

Universita' Degli Studi G. D'Annunzio Di Chieti

Hemic and Lymphatic Diseases

Italy

23/04/2026

Phase II

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

2025-520641-69-00Kidney disease

DrugsTacrolimus·Prednisolone·Obinutuzumab·Prednisone

Medizinische Universitaet Innsbruck

Immune System Diseases

Germany, Austria, France

23/04/2026

Phase I/II

A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.

2025-524438-24-00Type 2 Diabetes

Fractyl Health Inc.

Nutritional and Metabolic Diseases

Netherlands

23/04/2026

Phase IV

A randomized double-blind placebo-controlled study to demonstrate the efficacy of PMBL® sublingual tablets in reducing the incidence of respiratory tract infections in children aged 3-12 years (PIRTIK).

2025-524212-11-00Respiratory Tract Infections

Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz

Respiratory Tract Diseases

Poland

23/04/2026

Phase I

Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY

2025-524031-39-00Medulloblastoma (recurrent or progressive)

DrugEverolimus

Instytut Pomnik Centrum Zdrowia Dziecka

Nervous System Diseases

Poland

23/04/2026

Phase III

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

2025-522486-29-01Diabetes Mellitus, Cardiovascular disease, Overweight (BMI …

DrugSemaglutide

Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali

Cardiovascular Diseases

Italy

23/04/2026

Phase I

A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

2025-523978-16-00Type I diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Germany

23/04/2026

Phase I

Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms

2025-524814-27-00Malignant B-cell neoplasms

Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre

Hemic and Lymphatic Diseases

Spain

22/04/2026

Phase I/II

Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN)

2025-524279-22-00Spinal cord injury

Sinfatin S.L.

Musculoskeletal and Neural Physiological Phenomena

Spain

22/04/2026

Phase I/II

COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients

2025-524759-29-00Vulvar Squamous Cell Carcinoma (VSCC) patients

Centre Leon Berard

Female Urogenital Diseases and Pregnancy Complications

France

22/04/2026

Phase I

Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

2026-526040-13-00No medical condition.

Institut De Recherches Internationales Servier IRIS

Not possible to specify

Portugal

22/04/2026

Phase I

A FIRST-IN-HUMAN (FIH) PHASE 1/2 STUDY TO ASSESS SAFETY, TOLERABILITY, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF REGN17372, AN ANTI-GPRC5D X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY, IN COMBINATION WITH LINVOSELTAMAB, AN ANTI-BCMA X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

2025-522776-93-00Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals Inc.

Neoplasms

Greece

22/04/2026

Phase II

A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

2025-522076-85-00Rheumatoid arthritis

AstraZeneca AB

Immune System Diseases

Hungary, Spain, Bulgaria, Germany, Poland

22/04/2026

Phase II

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus.

2025-524514-28-00Type 2 Diabetes Mellitus

Corxel Pharmaceuticals Inc.

Nutritional and Metabolic Diseases

Poland

22/04/2026

Phase I/II

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

2025-523602-33-00Advanced or unresectable Hepatocellular Carcinoma (HCC)

DrugIpilimumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Poland, Spain, Germany, France, Italy

22/04/2026

Phase I

Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis

2025-522904-26-00Systemic Lupus Erythematosus (SLE) With or Without Active L…

Genentech Inc.

Immune System Diseases

Italy, Spain, France, Germany

22/04/2026

Phase I

A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.

2025-524594-16-00Patients with prostate cancer with: - suspected metastasis …

Philogen S.p.A.

Neoplasms

Italy

22/04/2026

Phase II

A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation

2025-523575-36-00Locally advanced head and neck squamous cell carcinoma (LA-…

DrugEzabenlimab

Cliniques Universitaires Saint-Luc

Neoplasms

Belgium

22/04/2026

Phase II

NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial

2025-523683-20-00Postmenopausal patients with small (pT1a-b pN0) hormone rec…

DrugsTamoxifen·Exemestane·Anastrozole·Letrozole

Unicancer

Neoplasms

France

21/04/2026

Phase III

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia

2025-524209-34-00Chemotherapy induced thrombocytopenia

Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Not possible to specify

France, Romania, Poland, Spain, Bulgaria

21/04/2026

Phase III

A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension

2025-523481-24-00Participants with Progressive Supranuclear Palsy Richardson…

Novartis Pharma AG

Nervous System Diseases

Netherlands, Germany, Spain, Italy, France, Belgium

21/04/2026

Phase I/II

A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).

2025-523971-46-00Diffuse cutaneous systemic sclerosis (dcSSc) Difficult to t…

Quell Therapeutics Limited

Musculoskeletal Diseases

Spain, Germany

21/04/2026

Phase I

A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

2025-521384-12-00obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Germany

21/04/2026

Phase II

Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

2025-525068-13-00Chronic Kidney Disease

DrugSurvodutide

Universitair Medisch Centrum Groningen

Nutritional and Metabolic Diseases

Germany, Spain, Netherlands

21/04/2026

Phase I/II

C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

2025-523524-53-00ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Pfizer Inc.

Neoplasms

Germany, Spain

21/04/2026

Phase III

J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

2025-523659-73-00Overweight, Obesity

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Spain, Romania, Belgium, Czechia

21/04/2026

Phase I

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myopathy

2025-524100-29-00Seropositive autoimmune disease: Sjogren’s disease or idiop…

Lakefront Biotherapeutics West LLC

Immune System Diseases

Czechia

21/04/2026

Phase II

Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study

2025-523260-20-00type 2 diabetes

DrugSemaglutide

Novo Nordisk A/S

Hormonal diseases

Spain, Hungary, Portugal, Poland, Slovakia, Croatia

21/04/2026

Phase I/II

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

2025-523474-16-00Malignancies with Documented KRAS, BRAF and Other Selected …

Institut De Recherches Internationales Servier IRIS

Neoplasms

France, Spain, Denmark, Italy

21/04/2026

Phase III

KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial

2025-523149-80-00Adult patients admitted to the ICU and receiving unplanned …

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

20/04/2026

Phase III

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia

2025-524366-21-00treatment-naive Chronic Lymphocytic Leukemia

BeOne Medicines I GmbH

Neoplasms

Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden

20/04/2026

Phase II

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochro…

CSL Behring LLC

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands

20/04/2026

Phase II

A randomized phase II study comparing the safety and efficacy of mifamurtide and standard therapy containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma

2026-525223-24-00Relapsed/refractory osteosarcoma, High-grade osteosarcoma

Instytut Matki I Dziecka

Neoplasms

Poland

20/04/2026

Phase III

A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with Non-permanent Atrial Fibrillation

2025-523860-19-00Non-permanent Atrial Fibrillation

Xyra LLC

Cardiovascular Diseases

Poland

20/04/2026

Phase I/II

Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases

2025-523630-59-00colon carcinoma metastases

HepaRegeniX GmbH

Neoplasms

France, Spain, Germany

20/04/2026

Phase III

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)

2025-523711-11-00Schizophrenia

Bristol-Myers Squibb Services Unlimited Company

Mental Disorders

Romania

20/04/2026

Phase I

A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

2025-522913-45-00Advanced relapsed or refractory ovarian cancer, Advanced re…

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Spain, France, Belgium, Germany

20/04/2026

Phase I

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code 06739-024, Vargem Grande Paulista – SP CNPJ No. 21,896,000/0001-91, in healthy adult, human subjects under fasting condition.

2025-524311-37-00chronic myeloid leukemia, Philadelphia chromosome-positive …

Sun Pharmaceutical Industries Limited

Neoplasms

Romania

20/04/2026

Phase I

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

2024-520125-36-00Relapsed or Refractory Acute Myeloid Leukemia; Acute Myelo…

DrugPivekimab Sunirine

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, Hungary, Czechia, France, Italy, Belgium

20/04/2026

Phase III

A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

2024-517337-41-00Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated N…

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Germany, Poland, Greece, France

20/04/2026

Phase III

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

2024-520014-22-00Locally advanced/metastatic urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France

20/04/2026

Phase I

Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.

2026-525823-26-00No medical condition.

Institut De Recherches Internationales Servier IRIS

Not possible to specify

Portugal

20/04/2026

Phase II

An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.

2025-522040-40-01Multiple Sclerosis

Universitair Ziekenhuis Antwerpen, Hospital Germans Trias I Pujol

Immune System Diseases

Belgium, Spain

20/04/2026

Phase III

C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY

2025-523660-21-00severe to moderately severe hemophilia B (FIX:C ≤ 2%), hemo…

Pfizer Inc.

Hemic and Lymphatic Diseases

Italy, Germany, France, Spain, Sweden, Greece

20/04/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis

2025-524002-16-00Amyotrophic Lateral Sclerosis

Ferrer Internacional S.A., Prilenia Therapeutics B.V.

Nervous System Diseases

Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain

20/04/2026

Phase III

J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ne…

DrugsEnfortumab Vedotin·Pembrolizumab

Eli Lilly & Co.

Neoplasms

Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain

20/04/2026

Phase IV

CoCo-PCOS - Comprehensive Health Effects of Combined Contraceptives: a 6-month randomized, controlled, open-label trial of E4+DRSP, EE20µg+DRSP, and DRSP-only in women with PCOS

2025-523358-15-00Contraception

Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu

Reproductive and Urinary Physiological Phenomena

Finland

20/04/2026

Phase IV

Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism

2025-523930-14-00Hypoparathyroidism

Region Midtjylland

Hormonal diseases

Denmark

20/04/2026

Phase I

A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

2025-523304-68-00Healthy participants and participants with type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Austria

19/04/2026

Phase II

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

2025-522790-10-00Non Small Cell Lung Cancer, Interstitial Lung Disease

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

17/04/2026

Phase II

A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease

2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

DrugVancomycin

MaaT PHARMA

Digestive System Diseases

Netherlands, Italy, France, Spain

17/04/2026

Phase III

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

2025-522748-42-00Ovarian cancer

DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel

Incyte Corp.

Neoplasms

Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium

17/04/2026

Phase IV

Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.

2025-521910-24-00Multiple Sclerosis

DrugCladribine

Aristotle University Of Thessaloniki

Nervous System Diseases

Greece

17/04/2026

Phase III

Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

2025-523717-29-00HFpEF or HFmrEF and obesity

Novo Nordisk A/S

Cardiovascular Diseases

Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France

17/04/2026

Phase I

A Phase 1 Study of AIR-001 in Adults with AATD.

2025-523558-14-00Alpha-1 Antitrypsin Deficiency

Airna Corp.

Respiratory Tract Diseases

Sweden, Ireland, Spain, Netherlands, Portugal, Germany

17/04/2026

Phase IV

CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial of E4+DRSP, EE20μg+DRSP and DRSP-only

2025-523359-71-00Contraception

Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu

Reproductive and Urinary Physiological Phenomena

Finland

17/04/2026

Phase III

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

2025-523544-12-00Myelodysplastic neoplasms/syndromes (MDS)

Takeda Development Center Americas Inc.

Hemic and Lymphatic Diseases

France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands

17/04/2026

Phase II

Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin

2025-524629-42-00Categoria 2, Patients with vegetable allergies due to sensi…

DrugOmalizumab

Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud

Not possible to specify

Spain

17/04/2026

Phase II

METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0

2025-522655-26-00METAREM:Patients with advanced cancer, as defined as unrese…

Unicancer

Neoplasms

France

16/04/2026

Phase IV

OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE

2025-524573-16-00Crohn's disease

i-GETAID

Digestive System Diseases

France

16/04/2026

Phase I/II

An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors

2025-521911-38-00Advanced HR+/HER- breast cancer

DrugsLeuprorelin Acetate·Goserelin·Letrozole·Fulvestrant

Novartis Pharma AG

Neoplasms

Italy, Germany, France, Czechia, Denmark, Spain

16/04/2026

Phase I

A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma

2025-524987-39-00Mild to Moderate Asthma

Aclaris Therapeutics Inc.

Respiratory Tract Diseases

Germany

16/04/2026

Phase I

A study to evaluate how well single and multiple doses of S072 are tolerated in healthy adult participants

2025-525039-15-01Pain

Sea4us Biotecnologia E Recursos Marinhos S.A.

Anesthesia and Analgesia

Spain

16/04/2026

Phase III

The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia

2025-523096-34-00B-cell Acute Lymphoblastic Leukemia

Prinses Maxima Centrum voor Kinderoncologie B.V.

Hemic and Lymphatic Diseases

Spain, Germany, Netherlands

16/04/2026

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia

2025-521628-31-00Friedreich’s ataxia is the most common inherited ataxia in …

DrugNomlabofusp

Larimar Therapeutics Inc.

Nervous System Diseases

France

16/04/2026

Phase III

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase III Therapeutic Superiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Diclofenac potassium + Thiocolchicoside to Diclofenac potassium (Cataflam®) in Patients with Acute Severe Low Back Pain.

2025-523153-33-00LOW BACK PAIN

DrugDiclofenac

Verisfield Single Member S.A.

Musculoskeletal Diseases

Cyprus, Greece

16/04/2026

Phase III

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

2025-523975-48-00Obesity

DrugBerobenatide

Metsera Inc.

Nutritional and Metabolic Diseases

Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany, Romania, Poland

16/04/2026

Phase I/II

Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

2025-523396-38-00Relapse or refractory (r/r) acute myeloid leukaemia (AML) a…

Aop Orphan Pharmaceuticals GmbH

Neoplasms

Spain

15/04/2026

Phase II

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer

2025-522162-75-00patients with asymptomatic active brain metastases from sma…

Academisch Ziekenhuis Maastricht

Respiratory Tract Diseases

Netherlands

15/04/2026

Phase II

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

2025-523509-13-00Hypochondroplasia

Qed Therapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Norway

15/04/2026

Phase III

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease

2024-518835-13-00Suspected Vascular Disease of supra-aortic (carotid/vertebr…

Guerbet, Bracco Imaging S.p.A.

Cardiovascular Diseases

Italy, France, Czechia, Hungary, Spain, Germany, Poland

15/04/2026

Phase I

GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

2025-524328-24-00Ulcerative colitis

Granite Bio AG

Digestive System Diseases

Germany

15/04/2026

Phase II

Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with a Glofitamab-based induction and consolidation concept

2025-523806-34-00relapsed/refractory Large B-Cell Lymphoma

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hemic and Lymphatic Diseases

Germany

15/04/2026

Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

2025-524136-19-00Selected Advanced or Metastatic Solid Tumors

BeOne Medicines AG

Neoplasms

Italy, France

15/04/2026

Phase I/II

A two-part study: open label, dose escalation phase aimed to evaluate the safety and tolerability of two different doses of allogeneic fibroblasts for the treatment of chronic refractory wounds and identifying the best dose for subsequent cohort expansion phase aimed to assess efficacy and confirm safety and tolerability

2025-522647-17-00Refractory wounds

Hmg Biologics S.r.l.

Skin and Connective Tissue Diseases

Italy

15/04/2026

Phase III

Efficacy of Dexmedetomidine on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Double-Blind Randomized Controlled Trial with Heart Rate Variability and Electroencephalography-Guided Anesthesia

2025-524086-24-00Emergence delirium

DrugDexmedetomidine

Akershus University Hospital

Nervous System Diseases

Norway

15/04/2026

Phase I

A study in healthy men to test how bosentan influences the amount of zongertinib in the blood

2025-523193-16-00Healthy volunteer trial

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

15/04/2026

Phase III

A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome

2025-523157-34-00Rett syndrome

UCB Biosciences Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Poland, France, Hungary, Belgium, Italy, Germany

15/04/2026

Phase I

A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults

2025-524043-12-00atrial fibrillation, ischemic stroke, transient ischemic at…

Bayer AG

Cardiovascular Diseases

Germany

15/04/2026

Phase I/II

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

2025-522318-21-00Neoplasms, Colorectal

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Denmark, Spain, Sweden, Netherlands, France

14/04/2026

Phase I

A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

2025-521000-22-00Patients with advanced malignancies

Novartis Pharma AG

Neoplasms

Spain, Italy, France

14/04/2026

Phase I

A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

2025-523847-36-00Participants with Mild, Moderate, or Severe Hepatic Impairm…

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Hungary

14/04/2026

Phase II

68Ga-FAPI-46 PET for Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease

2024-511977-31-01giant cell arteritis - polymyalgia rheumatica spectrum dise…

Drug[68Ga]Ga-FAPI-46

Universitair Medisch Centrum Groningen

Cardiovascular Diseases

Netherlands

14/04/2026

Phase IV

A low-intervention randomised, double-blind, placebo-controlled pilot trial evaluating the feasibility, tolerability and adherence of alternate-day oral Duroferon (ferrous sulphate) in adolescent girls with iron deficiency, and the diagnostic performance of the IRON-5 screening tool (IRONGIRLS-PILOT).

2025-522498-12-00iron deficiency in adolescent girls

Region Skane

Not possible to specify

Sweden

14/04/2026

Phase II

Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).

2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Nervous System Diseases

Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland

14/04/2026

Phase IV

A single-center, randomized, single-blind, phase 4 study to evaluate the enhancement of mucosal immunity in infants through maternal vaccination during breastfeeding (MEALAC-01).

2025-524862-12-00Measles

DrugYellow fever vaccine

Universite Libre de Bruxelles

Virus Diseases

Belgium

14/04/2026

Phase I/II

Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors

2025-524111-37-00advanced solid tumors

Ottimo Pharma Limited

Neoplasms

Ireland, Spain, Portugal

14/04/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer

2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer

DrugPegfilgrastim

Genmab A/S

Neoplasms

Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland

14/04/2026

Phase II

Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125

2025-521827-61-00refractory/relapsed multiple myeloma

DrugTeclistamab

Fondazione G.I.M.Em.A Franco Mandelli Ets

Hemic and Lymphatic Diseases

Italy

14/04/2026

Phase II

Standardized Phleum pratense in TBU/ml in liquid formulation for sublingual immunotherapy: Phase II, randomized dose determination clinical trial. DEDO-G Study.

2025-522730-31-00Allergic rhinitis/rhinoconjunctivitis caused by grass polen…

Asac Pharmaceutical Inmunology S.A.

Immune System Diseases

Spain

14/04/2026

Phase II

A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)

2025-523428-39-00Mantle Cell Lymphoma

Fondazione Italiana Linfomi Ets

Hemic and Lymphatic Diseases

Italy

14/04/2026

Phase II

C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

2025-522965-31-00Atopic Dermatitis

Pfizer Inc.

Skin and Connective Tissue Diseases

Poland, Czechia, Germany, Bulgaria, France

14/04/2026

Phase I

A clinical trial of MK-6050 in healthy participants (MK-6050-002)

2026-525625-21-00Hidradenitis

Merck Sharp & Dohme LLC

Immune System Diseases

Belgium

13/04/2026

Phase III

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

2025-521571-30-00Young Adults and adults with R/R B-cell acute lymphoblastic…

DrugsImmunoglobulins·Levofloxacin·Azithromycin·Amoxicillin

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

13/04/2026

Phase I/II

Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

2024-520052-19-04Malignant Melanoma

Amsterdam UMC Stichting

Therapeutics

Netherlands

13/04/2026

Phase II

A randomized, placebo-controlled trial to assess the efficacy, tolerability, and pharmacokinetics of clemastine in children and adults with Pitt-Hopkins syndrome

2025-524195-29-00Pitt-Hopkins syndrome

Amsterdam UMC Stichting

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

13/04/2026

Phase II

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)

2025-523117-28-00Relapsed or Refractory Multiple Myeloma

Glaxosmithkline Research & Development Limited

Neoplasms

France, Germany, Greece, Netherlands, Spain

13/04/2026

Phase II

Randomized adaptive assessment of post COVID syndrome treatments (RAPID): Evaluating the Efficacy of Bupropion for the Treatment of Post-COVID-19 Syndrome-associated Fatigue (ELAPSE)

2025-524443-12-00Post Covid Syndrome (PCS)

Goethe University Frankfurt

Virus Diseases

Germany

13/04/2026

Phase III

Prevention of chronic headache with anti-CGRP antibody treatment in patients with idiopathic intracranial hypertension

2025-524822-16-00Idiopathic intracranial hypertension

Rigshospitalet

Nervous System Diseases

Denmark

13/04/2026

Phase I

A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

2025-522953-21-00unresectable advanced or metastatic solid cancer

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Spain

13/04/2026

Phase II

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients with Primary Knee Osteoarthritis

2025-524668-39-00Knee Osteoarthritis

Enlivex Therapeutics Ltd.

Musculoskeletal Diseases

Denmark, Poland

13/04/2026

Phase IV

Methotrexate in paediatric and adolescent Crohn’s disease: an observational study

2025-524129-42-00Crohn’s disease

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

11/04/2026

Phase III

A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

2025-524038-24-00Focal Epilepsy

Praxis Precision Medicines Inc.

Nervous System Diseases

Poland, Germany, Czechia, Italy, Spain

10/04/2026

Phase I

Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients with Acute Myeloid Leukaemia (AML): TOCIVENA

2025-524725-41-00Acute Myeloblastic Leukemia

Centre Hospitalier Universitaire De Nantes

Not possible to specify

France

10/04/2026

Phase I/II

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)

2025-522207-15-01Stargardt Disease (STGD1)

Aavantgarde Bio S.r.l.

Eye Diseases

Belgium, Italy, Netherlands, Norway

10/04/2026

Phase II

A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma

2025-523180-38-00Uncontrolled Moderate to Severe Eosinophilic Asthma

Kymera Therapeutics Inc.

Immune System Diseases

Spain, Romania, Slovakia, Poland, Germany, Italy, Belgium, Austria

10/04/2026

Phase III

LIBRETTO: Stimulan™ Local Antibiotic Delivery System Versus 4-Week Systemic Antibiotic Therapy for Diabetic Foot Osteomyelitis – A Prospective, Randomized, Controlled Trial

2025-524723-52-00Diabetic Foot Osteomyelitis

DrugsClindamycin·Ciprofloxacin·Levofloxacin·Metronidazole

Pirkanmaan hyvinvointialue

Bacterial Infections and Mycoses

Finland

10/04/2026

Phase II

A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)

2025-520976-25-00Relapsed/refractory multiple myeloma

DrugMezigdomide

Centre Hospitalier Universitaire De Saint Etienne

Hemic and Lymphatic Diseases

France

09/04/2026

Phase I

A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer

2025-521001-40-00Advanced Malignancies and Hepatic Impairment

Novartis Pharma AG

Neoplasms

Spain, France, Italy

09/04/2026

Phase I

Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

2025-522916-17-00Urinary Tract Infections

Glaxosmithkline Research & Development Limited

Bacterial Infections and Mycoses

Spain, Poland

09/04/2026

Phase II

Retinoic acid and sperm production in infertile men

2024-519644-33-00oligozoospermia

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

09/04/2026

Phase I/II

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies

2025-523547-35-00Advanced Solid Tumor Malignancies

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Spain

09/04/2026

Phase II

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.

2025-522867-13-00Non Small Cell Lung Cancer

Merus B.V.

Not possible to specify

Spain, Belgium, Netherlands, Poland, Italy, France

09/04/2026

Phase I/II

C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors

2025-523526-40-00Advanced Solid Tumors

Pfizer Inc.

Neoplasms

Italy, Spain, France, Germany

09/04/2026

Phase I/II

C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

2025-523525-17-00Unresectable Locally Advanced or Metastatic Hepatocellular …

DrugsPF-08634404·Ipilimumab

Pfizer Inc.

Neoplasms

Spain, Italy, Germany, France

09/04/2026

Phase I

Study of diclofenac skin reservoir formation and emptying after Voltaren Emulgel 2.32% application in healthy participants

2025-524764-38-00For the local, symptomatic treatment of pain in acute bruis…

Haleon CH SARL

Therapeutics

Germany

09/04/2026

Phase III

Efficacy of intravenous dexamethasone in prolonging the duration of spinal anesthesia with chloroprocaine in knee arthroscopy.

2023-505247-39-00Knee arthroscopy

DrugDexamethasone

Centre Medico Chirurgical Ambroise Pare Hartmann

Anesthesia and Analgesia

France

08/04/2026

Phase II

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

2025-521090-14-00Patients with relapsed/refractory symptomatic multiple myel…

DrugsMezigdomide·Carfilzomib·Dexamethasone

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

08/04/2026

Phase III

FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial

2024-514964-24-00ulcerative colitis

DrugsFilgotinib·Ustekinumab·Vedolizumab·Infliximab

University Hospital Of Clermont-Ferrand

Digestive System Diseases

France

08/04/2026

Phase III

A randomized, Phase 3, open-label study to investigate pharmacokinetics, safety, and efficacy of subcutaneous compared to intravenous frexalimab in adult participants with multiple sclerosis.

2024-519304-28-00Multiple Sclerosis

Sanofi-Aventis Recherche & Developpement

Nervous System Diseases

Belgium, Spain, Italy

08/04/2026

Phase I

A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

2025-524157-13-00Chronic Hepatitis B

Precision Biosciences Inc.

Virus Diseases

Romania, France

08/04/2026

Phase II

ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.

2025-522288-13-00Patients with pretreated extensive-stage small cell lung ca…

ETOP IBCSG Partners Foundation

Neoplasms

France, Greece, Spain, Italy

08/04/2026

Phase III

An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

2025-522460-33-00Stargardt Disease

DrugTinlarebant

Belite Bio Inc.

Eye Diseases

Netherlands, France, Belgium

07/04/2026

Phase IV

Pilot Study - Safety and Efficacy of Dalbavancin in Early Outpatient Treatment of Erysipelas and Limited Cellulitis

2025-524877-18-00Acute bacterial skin and skin structure infection (ABSSSI) …

DrugDalbavancin

Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Skin and Connective Tissue Diseases

Austria

07/04/2026

Phase III

C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

2025-523522-41-00Extensive-Stage Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Atezolizumab·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Germany, Spain

07/04/2026

Phase III

Sevoflurane vs. propofol for general Anesthesia in patients with acute ischemic stroke treated with endoVascular treatmEnt (SAVE trial)

2025-523709-13-00Acute ischemic stroke

DrugPropofol

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Anesthesia and Analgesia

Spain

07/04/2026

Phase II

Treatment of low-flow vascular malformations with bleomycin electrosclerotherapy (BEST)

2025-524123-45-00VASCULAR MALFORMATION

Institute Of Oncology Ljubljana

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Slovenia

07/04/2026

Phase I

A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people

2025-525025-12-00Iron overload from thalassemia, transfusion-dependent myelo…

Pharmacosmos A/S

Hemic and Lymphatic Diseases

Netherlands

07/04/2026

Phase III

A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

2025-521108-23-00Chronic Obstructive Pulmonary Disease

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania

07/04/2026

Phase III

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants with Diabetic Macular Edema (DME) (EYP-1901-303)

2025-523937-25-00Diabetic Macular Edema (DME)

Eyepoint Inc.

Eye Diseases

Germany, Poland, Slovakia

07/04/2026

Phase IV

Application of radiomics in molecular imaging (18F-FDG-PET/CT) for diagnosis and follow-up of cardiovascular device infections: PREDICT study

2025-524624-21-00Cardiovascular device infections

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Virus Diseases

Spain

07/04/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)

2024-520444-42-00Overweight or obesity, and knee osteoarthritis

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Italy, Greece, Spain, Bulgaria, Denmark, Poland

07/04/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)

2024-520445-23-00Overweight or obesity, and knee osteoarthritis

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Greece, Poland, Spain, Bulgaria, Italy, Denmark

07/04/2026

Phase III

Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis

2024-511593-70-00Polyarticular-course juvenile idiopathic arthritis

Alfasigma S.p.A.

Musculoskeletal Diseases

Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia

07/04/2026

Phase II

The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia

2025-524774-42-00Male Infertility

Herlev Hospital

Male Urogenital Diseases

Denmark

07/04/2026

Phase IV

Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial

2025-524440-35-00metastatic castration resistant prostate cancer (mCRPC)

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

07/04/2026

Phase II

Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase II Trial Investigating the Effect of Valproic Acid in Women with Adenomyosis.

2025-523076-23-00Adenomyosis

CCDRD Cooperative Clinical Drug Research and Development AG, Nadezhda Reproductive Science OOD

Female Urogenital Diseases and Pregnancy Complications

Bulgaria

03/04/2026

Phase I

A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer

2024-520286-31-00Hot Flush

Astellas Pharma Global Development Inc.

Male Urogenital Diseases

Bulgaria

03/04/2026

Phase III

Evaluation of the efficacy and safety of bimekizumab (BZK) or adalimumab (ADA) in the treatment of anterior chest wall pain associated with active axial spondyloarthritis refractory to NSAIDs with hypothesis of superiority of bimekizumab. Randomized, open-label, in parallel arms, head to head trial (ThoracSPA)

2025-520632-42-00axial or predominantly axial SpA with or without psoriasis

DrugsBimekizumab·Adalimumab

Centre Hospitalier Universitaire Rouen

Musculoskeletal Diseases

France

03/04/2026

Phase II

A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability via Autoinjector Device versus Syringe in Patients with Multiple Sclerosis

2025-523757-33-00multiple sclerosis

Tg Therapeutics Inc.

Nervous System Diseases

Poland

03/04/2026

Phase I

Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria

2025-522630-31-00Phenylketonuria

Agios Pharmaceuticals Inc.

Nutritional and Metabolic Diseases

Poland

03/04/2026

Phase II

Open-Label, Multi Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

2025-522441-21-00Parkinson's Disease

Askbio Inc.

Nervous System Diseases

Poland

03/04/2026

Phase III

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases

2025-523017-28-00Locoregional Recurrence of Squamous Cell Carcinoma of the H…

Rakuten Medical Inc.

Neoplasms

Poland

03/04/2026

Phase III

Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, double-blind, placebo-controlled, phase 3 trial PEACH 2

2024-515663-59-00intracerebral haemorrhage

DrugLevetiracetam

Hospices Civils De Lyon

Nervous System Diseases

France

02/04/2026

Phase II

Efficacy and safety of a novel dual pH-dependent delayed-release ColeseveLam for the trEatment of bile Acid diarrhoea: a Randomized, double-blind, parallel-group, placebo-controlled clinical trial - CLEAR

2025-523868-20-00Bile acid diarrhoea

Monteresearch S.r.l.

Digestive System Diseases

Italy

02/04/2026

Phase II

TREAT-EC (Tirzepatide in the treatment of endometrial cancer) - a clinical trial

2025-523877-40-00Endometrial adenocarcinoma

DrugsLevonorgestrel·Tirzepatide

University College Dublin

Neoplasms

Ireland

02/04/2026

Phase II

Colonic Intramural Injections of Botulin toxin versus placebo to treat fragmented defecation and urgency after restorative total mesorectal excision (TME) for rectal cancer

2025-524342-96-00Rectal Cancer

DrugBotulinum toxin type A

UZ Leuven

Digestive System Diseases

Belgium

02/04/2026

Phase II

Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

2026-525349-65-00Diabetic Retinopathy, Retinal Vein Occlusion

Annexin Pharmaceuticals AB (publ)

Eye Diseases

Germany

02/04/2026

Phase I

A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity

2025-524206-15-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Germany

02/04/2026

Phase I

Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.

2025-522246-43-00Treatment of symptomatic anemia associated with chronic ren…

Blau Farmaceutica S.A.

Hemic and Lymphatic Diseases

Germany

02/04/2026

Phase III

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER RANDOMIZED, CONTROLLED TRIAL (VESPER-4)

2025-523974-18-00Obesity

DrugBerobenatide

Metsera Inc.

Nutritional and Metabolic Diseases

Germany, Hungary, Slovakia, Poland, Spain, Czechia, Romania, Bulgaria

02/04/2026

Phase II

L-Thyroxine for the treatment of acute unilateral vestibulopathy (AUVP): a monocentric, double-blind, placebo-controlled trial (T4U)

2024-519515-34-00Patients with acute unilateral vestibulopathy (AUVP)

Klinikum der Universitaet Muenchen AöR

Nervous System Diseases

Germany

02/04/2026

Phase III

J3R-MC-YDAN - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4) J3R-MC-YOA1: Intervention-Specific Appendix 1 (ISA1) for Eloralintide in Participants with Osteoarthritis Knee Pain J3R-MC-YOA2: Intervention-Specific Appendix 2 (ISA2) for Eloralintide in Participants with Osteoarthritis Knee Pain

2025-523768-19-00Osteoarthritis, Overweight or Obesity

Eli Lilly & Co.

Nutritional and Metabolic Diseases

Denmark, Belgium, Germany, Czechia

02/04/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy

2025-522343-18-00Autosomal Dominant RYR1-Related Myopathy

Rycarma Therapeutics Inc.

Musculoskeletal Diseases

Netherlands, Spain, France, Germany

02/04/2026

Phase III

AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A Multicentre, Randomized Study

2023-509421-41-03Vaginal flora abnormalities, High risk preterm birth pregna…

DrugsAzithromycin·Metronidazole

Assistance Publique Hopitaux De Marseille

Bacterial Infections and Mycoses

France

01/04/2026

Phase III

A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)

2025-520479-25-00Symptomatic Venous Thromboembolism (VTE)

DrugsCenvacibart·Acetylsalicylic acid

Regeneron Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Greece, Italy, Spain

01/04/2026

Phase III

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

2025-522567-15-00Plaque Psoriasis

Takeda Development Center Americas Inc.

Skin and Connective Tissue Diseases

Spain, Poland, Germany, Italy

01/04/2026

Phase I

A First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MR-L45 in Healthy Adults

2025-524899-40-00Autosomal Dominant Polycystic Kidney Disease

Mironid Limited

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

01/04/2026

Phase III

PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial

2025-524229-41-00Triple negative breast cancer

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasms

Netherlands

01/04/2026

Phase I

A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up into the Blood of Healthy Adults After Taking Different Tablets of the Study Medicine Called Ibuzatrelvir.

2025-525041-43-00Coronavirus disease 2019

Pfizer Inc.

Virus Diseases

Belgium

01/04/2026

Phase III

Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).

2025-523239-21-00Juvenile idiopathic arthritis

Alfasigma S.p.A.

Immune System Diseases

France, Germany, Poland, Belgium, Hungary, Spain, Czechia, Greece, Italy

01/04/2026

Phase I

A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

2025-522523-96-00Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphom…

Kyowa Kirin Inc.

Neoplasms

Spain, Italy

01/04/2026

Phase II

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa

2025-521865-29-00moderate-to-severe hidradenitis suppurativa

Almirall S.A.

Skin and Connective Tissue Diseases

Bulgaria, Spain, France, Poland, Germany

01/04/2026

Phase IV

GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY

2025-521101-40-00CHRONIC DECOMPENSATED HEART FAILURE

Centre Hospitalier Regional Universitaire

Cardiovascular Diseases

France

31/03/2026

Phase II

A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.

2025-523460-21-00Metastatic breast cancer

DrugsCapivasertib·Elacestrant·Trastuzumab deruxtecan·Fulvestrant

Centro Di Riferimento Oncologico Di Aviano

Neoplasms

Italy

31/03/2026

Phase II

A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)

2025-522440-41-00Hidradenitis Suppurativa

Bluefin Biomedicine Inc.

Immune System Diseases

Spain, Germany, Czechia, Poland, Bulgaria

31/03/2026

Phase I/II

Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.

2025-522697-37-00Amyotrophic Lateral Sclerosis

VectorY Therapeutics B.V.

Nervous System Diseases

Netherlands, Belgium, Spain

31/03/2026

Phase III

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS trial)

2025-521936-12-00Adults with Type 2 Diabetes and/or Metabolic Syndrome on g…

NewAmsterdam Pharma B.V.

Cardiovascular Diseases

Czechia, Slovakia, Netherlands

31/03/2026

Phase II

OmaMig Pilot: An open-label, phase IIa, single arm pilot study evaluating the potential clinical benefit and safety of omalizumab in adults with episodic migraine.

2025-522448-41-00Episodic migraine

DrugOmalizumab

Oslo University Hospital HF

Nervous System Diseases

Norway

31/03/2026

Phase I

An Open-Label, Single-Arm Phase 1 Trial to Evaluate The Safety, Tolerability and Efficacy of Vididencel in Chronic Phase Chronic Myeloid Leukemia Patients with Measurable Residual Disease Unable to Meet Requirements of Treatment Free Remission under Tyrosine Kinase Inhibitor Treatment

2025-524587-37-00Chronic Phase Chronic Myeloid Leukemia

Mendus B.V.

Neoplasms

Norway

31/03/2026

Phase I

SIE-1

2025-523269-31-00Hormone receptor-positive early breast cancer in post-menop…

Laboratorios Farmaceuticos Rovi S.A.

Neoplasms

Spain

31/03/2026

Phase I/II

CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III

2023-506019-16-03TRIPLE NEGATIVE BREAST CANCER

Celica d.o.o.

Neoplasms

Slovenia

31/03/2026

Phase I/II

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)

2024-519786-22-01metastatic non-small cell lung cancer (NSCLC)

DrugsRamucirumab·Rilvegostomig

AstraZeneca AB

Neoplasms

Germany, Spain, France, Poland, Belgium, Netherlands, Italy

30/03/2026

Phase I/II

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination with Other Anticancer Agents in Participants with Metastatic Prostate Cancer (ANDROMEDA)

2024-516976-14-00Metastatic Prostate Cancer

AstraZeneca AB

Male Urogenital Diseases

Netherlands, Spain

30/03/2026

Phase IV

Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study

2025-524751-32-00Acute coronary syndrome

Fundacion Epic

Cardiovascular Diseases

Spain

30/03/2026

Phase III

Intranasal insulin for the prevention of delirium in ICU patients undergoing elective cardiac surgery: a randomized, double blind, placebo controlled pilot trial (INSPIRE)

2025-524680-21-00Delirium

Radboud universitair medisch centrum Stichting

Nervous System Diseases

Netherlands

30/03/2026

Phase IV

Healing Diabetic Foot Ulcers with Semaglutide

2025-524738-24-00Diabetic foot ulcer

Radboud universitair medisch centrum Stichting

Cardiovascular Diseases

Netherlands

30/03/2026

Phase I

Rituximab for Treatment of Checkpoint Inhibitor Induced Immune Related Adverse Events

2026-525728-18-00All CTCAE (v. 6.0) grade 2-4 immune-related adverse events

Region Hovedstaden

Immune System Diseases

Denmark

30/03/2026

Phase II

A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder

2025-524163-21-00Cannabis dependence (Cannabis Use Disorder or CUD)

Region Hovedstaden

Behavior and Behavior Mechanisms

Denmark

30/03/2026

Phase IV

Identification of mitochondrial biomarkers reflecting omaveloxolone treatment (in FA patients)

2025-523881-26-00Friedreich's ataxia

Fakultni Nemocnice V Motole

Nervous System Diseases

Czechia, Poland

30/03/2026

Phase III

2025-523938-10-00Diabetic Macular Edema (DME)

Eyepoint Inc.

Eye Diseases

Hungary, Czechia, Germany

30/03/2026

Phase III

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder

2025-523618-10-00Major Depressive Disorder

Xenon Pharmaceuticals Inc.

Mental Disorders

Finland, Poland, Romania, Slovakia, Spain, Germany

30/03/2026

Phase IV

TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)

2025-524819-37-00obstructive sleep apnea

DrugSemaglutide

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Respiratory Tract Diseases

Spain

30/03/2026

Phase I

Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia

2025-522617-39-00Refractory hyperlipidemia

Verve Therapeutics Inc.

Cardiovascular Diseases

Netherlands

30/03/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)

2024-520442-36-00Overweight or obesity, and obstructive sleep apnoea not tre…

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Denmark, Poland, Spain, Germany

30/03/2026

Phase I

A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD)

2025-524468-40-00chronic Graft-versus-Host-Disease (cGvHD)

Universitaetsklinikum Erlangen AöR

Immune System Diseases

Germany

27/03/2026

Phase I

Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

2026-525449-57-00Parkinson desease

Orion Corporation

Nervous System Diseases

Czechia

27/03/2026

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 6 November 2026. https://priyalifescience.com/clinical-trials-europe?page=3

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,777 trial records at the last sync on 06 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

How many clinical trials does CTIS hold?

CTIS held 12,777 trial records at the last sync. Of the 2,556 most recently authorised trials shown in this register, 789 are Phase III. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

→

Browse trials by member state

Spain (1075) France (930) Germany (898) Italy (778) Poland (619) Netherlands (547) Belgium (455) Czechia (341) Denmark (319) Hungary (254) Greece (237) Austria (219) Romania (219) Bulgaria (218) Sweden (200)

→

Browse trials by condition

Advanced solid tumors (23) Atopic Dermatitis (19) Non-Small Cell Lung Cancer (15) Obesity (14) Parkinson’s disease (14) Multiple sclerosis (13) Rheumatoid arthritis (13) Breast Cancer (11) Ulcerative colitis (11) Prostate Cancer (10)

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.